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ABSTRACT 
 
In terms of prevalence, human suffering and costs dengue infections are the most 
important arthropod-borne viral disease worldwide. Dengue virus (DENV) is a mosquito-
borne flavivirus and the etiological agent of dengue fever and dengue hemorrhagic fever. 
Thus, development of a safe and efficient vaccine constitutes an urgent necessity. Besides 
the traditional strategies aim at generating immunization options, the usage of viral 
vectors to deliver antigenic stimulus in order to elicit protection are particularly attractive 
for the endeavor of a dengue vaccine. The viral vector (MVvac2) is genetically 
equivalent to the currently used measles vaccine strain Moraten, which adds practicality 
to my approach. The goal of the present study was to generate a recombinant measles 
virus expressing structural antigens from two strains of DENV (DENV2 and DENV4) 
The recombinant vectors replication profile was comparable to that of the parental strain 
and expresses either membrane bound or soluble forms of DENV2 and DENV4 E 
glycoproteins. I discuss future experiments in order to demonstrate its immunogenicity in 
our measles-susceptible mouse model. 
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Chapter 1-INTRODUCTION 
 
1.1Dengue viral infections are the cause of major public health problems worldwide. 
Dengue infection has increased the global health concern. More than 100 countries, 
where dengue infection is now endemic, include both tropical and subtropical countries 
that have been affected. World Health Organization (WHO) reports “two fifths of the 
world's population is at risk of dengue infections with an increasing in the annual number 
of cases “(See Figure1). Unfortunately, Dengue causes hospitalization and death mostly 
among children. Dengue infection became a very severe problem after 2000 where a 
sharp increment in the number of reported dengue infection cases reached 100 million 
cases, including one million case of severe dengue infections (dengue hemorrhagic fever, 
DHF and dengue shock syndrome, DSS) which lead to 22,000 deaths (6). Generally, 
Figure 1, Represent the global distribution of Dengue virus. Dengue virus (DENV) is 
endemic in most of the   World’s tropical and subtropical areas. The number of dengue fever 
DF and  dengue hemorrhagic fever DHF cases during one year are shown. Nature reviews 
microbilogy(1) 
2 
 
Dengue virus (DENV) infection results in a spectrum of clinical manifestation ranging 
from asymptomatic to dengue fever (DF) which is characterized by flu-like-symptoms 
(headache, fever and severe eye pain), muscles pain, joint pain, abdominal pain, nausea 
and rash (6-8). Common laboratory abnormalities in DF are elevation in serum 
transaminases enzymes (indicator of liver damage), thrombocytopenia and leucopenia (9-
12). Full recovery from DF can be expected in most of the cases. Sometimes, 
DENVinfections might cause life threatening DHF or DSS. DHF is characterized by all 
DF symptoms combined with hemorrhagic tendencies evidenced by spontaneous 
bleeding from the mucosa, gastrointestinal tract and other locations, thrombocytopenia 
(low platelet count) and evidence of plasma leakage due to increased vascular 
permeability (13-15). Characteristically, patients with a high tendency to hemorrhage 
present a positive tourniquet sign as evidence for capillary hemorrhage. DSS is 
characterized by all DHF symptoms combined with rapid or weak pulse and narrow pulse 
pressure defined as the difference between systolic and diastolic blood pressure. 
Hemodynamically, the shock syndrome is associated mainly to a reduction in peripheral 
resistance caused by a generalized vasodilatation (13, 14). These severe dengue infections 
might result in death mostly among patients younger than 15 years old. The WHO 
classified DHF in four grades from I to IV. DHF grades I and II represent mild cases 
without hemorrhagic manifestations or shock and high number of recovering cases. 
Grades III and IV, cases are more severe and are characterized by hemorrhage leading to 
shock. The life-threatening DSS stage occurs in the early stage of grade III cases. If the 
patients do not receive prompt and appropriate treatment, severe cases of DHF and DSS  
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may be lethal within 12 to 36 hours after the beginning of a grade IV DHF (16). 
DENV is the most important arbovirus (anthropoid –borne) disease that is transmitted to 
human by mosquito bites. Anthropoid vector includes Aedes.aegypti, which is the 
predominant vector, and Aedes.albopictus, which can sustain transmission in some 
endemic areas (17). Aedes mosquitos are the main cause of the disease spreading 
worldwide, including South America, North America, Africa, Asia and Australia. 
Mosquitos are infected when it imbibes virus with blood meal from an infected host. 
After the ingestion of infectious blood meal, the virus infects and multiplies in midgut 
Figure 2. Represent the transmission cycles of Dengue virus. Enzootic or sylvatic cycle 
takes place in Asia forests has a minimal contribution to the urban epidemic cycle. The 
amplification of Dengue virus in the human body result in generating high titer virus in the 
blood of infected human which is enough to transmitting virus to mosquito to maintain the 
virus through urban epidemic cycle with no need to the enzootic cycle. Which make the 
enzootic cycle has no impact in the widespread of Dengue virus in the human population 
comparing to other arboviruses such as yellow fever virus where the enzootic cycle contribute 
to the widespread of the virus among the human population. Nature Reviews Microbioloy(1) 
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epithelial cells (18). The virus amplification happens in other mosquito’s tissues and 
cells, which results in the distribution of the virus through the hemocele  (the mosquito 
circulatory system). After the amplification of the virus, it will infect the epithelial cells 
of the salivary gland and the mosquitos will be capable of transmitting the virus in the 
infected salivary fluid to humans by feeding. The time period from the infection of a 
mosquito from an infected host to when the salivary glands became infected and the virus 
can be transmitted is called “extrinsic incubation period” (EIP). That is takes about 8 to 
12 days depending on the temperature (see figure 3) (18). Mosquitoes are cold blooded 
and their metabolism and biology are greatly affected by environmental conditions. 
Temperature is one of the most important factors in the viral transmission by mosquitoes. 
The temperature directly affects the viral replication in the mosquitoes’ cells and the 
increment in temperature increases the rate of the virus replication. However, the 
mortality rates of mosquitoes increase at high temperature. The effects of temperature on 
mosquitoes and viral replication, may explain the distribution of the DENV infection and 
vector in the tropical and subtropical countries, since they have suitable environmental 
conditions for the virus replication and for the mosquitos to thrive (18). The disease 
control is cumbersome since the geographic expansion of the vector has increased the 
circulation of viruses worldwide. Prior to the 1970s, DHF was only reported in five 
countries located in South East Asia (13). However, now DHF has been reported in more 
than 60 countries and DENV is endemic in more than 100 countries. This dramatic 
increase in Dengue infection is due to the geographical expansion of Ae. aegypti after the 
vector control efforts decline. Other arboviruses required an enzootic cycle (non-human  
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primates-mosquito-non-human primates) for virus amplification and maintenance of virus 
transmission in human (19). In contrast, DENV is the only virus among the arboviruses 
that can be amplified and maintained by urban epidemic transmission cycle (human-
mosquito-human). Enzootic cycle of Dengue transmission does exist in the forests of 
Asia, but the contribution of this cycle to the urban epidemic cycle is minimal (see figure 
2) (20). Which make the control of the virus transmission by destroying enzootic cycle is 
not an option for DENV. Once the infected mosquitoes transmit the virus to a healthy 
human host, the virus will replicates into the resident cells at the site of mosquito bite and 
the virus will be amplified and spread to infect other tissue and organs (See below). The 
time between a human being infected and the onset of symptoms due to infection known 
as “intrinsic incubation period” (IIP) ranges from 3 to 14 days, but it generally 4 to 7 days 
Figure 3, Represent the feeding and transmission cycle of mosquito borne Dengue 
virus. In host #1 high titer virus in the blood occurs at levels that can infect mosquitoes 
for 2 to 6 days. After a mosquito ingest virus with blood meal, it takes 8 to 14 days for the 
virus to infect the slavery glands, by that time the mosquito became infected and can 
transmitted the virus when bite host#2. This period called Extrinsic incubation period 
(EIP). The time it takes from infection of host#2 to the onset of symptoms is called 
intrinsic incubation period(IIP) in host and it takes 4 to 7 days.  
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(see figure 3). 
 
1.2 The pathogenesis of Dengue infection depends on the cell and tissue tropism of 
DENV. DENV is transmitted by mosquito bites that make the human body’s skin the 
entry route of the virus (20). After mosquito bites DENV will pass the epithelial cells 
surface where it will reach the subepithelial tissues (21, 22). As a result, the virus will 
infect the lymphatic cells that are present in the subepithelial tissues. Epidermal dendritic 
cells, known as Langerhans cells, are the main targets of infection; these immature 
dendritic cells have a great phagocytic capacity. DENV infection induces 
maturation/migration of these cells. The infection of these dendritic cells will cause 
lymphatic spread of DENV (23). The infected dendritic cells will migrate to the lymph 
nodes where monocytes and macrophages are recruited in which they will be also 
infected by DENV(24-27).  The infected macrophage and monocytes will circulate 
through the blood stream, which is known as primary Viremia (this term denotes the 
presence of virus infectivity in the blood stream).  Once the virus gets into the blood 
stream the viral infection will be localized in the other organs (see figure 4). The 
secondary viremia reflects the reboots replication of DENVin host cells; its intensity is 
about 105 to 106 Dengue infectious units per ml at its peak (28). It is sustained by 
infection of blood –derived monocytes, myeloid dendritic cells and tissues macrophages 
(including spleen and liver macrophages). By this time Dengue infection will have two 
impacts: the immune responses and the replication of the virus in other tissue and organs. 
Infected macrophage will cause the infection of liver, spleen and bone marrow stromal 
cells (see figure 4). Other organs have tropism for Dengue infection including kidney, 
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lung and the central nervous system (28-30).  Several organs infection by Dengue is one 
of the main events associated with DHF and DSS, where the viraemia is generally 10-100 
fold greater than in DF (31, 32). Replication of DENV has different effect on different 
organs and tissues. For instance, infected liver macrophages will infect both hepatocytes 
and Kupffer cells resulting in necrosis and apoptosis in liver (33). As a result, decreases 
in the liver function will happen which cause releasing of toxic products, decreasing the 
synthesis of coagulation factors and decreasing in the level of platelets.  Losing liver 
function develops coagulopathy disorder that may result in progressing of Dengue fever 
to DHF and DSS. Replication of DENV in bone marrow stromal cells causes suppression 
of haemopoiesis (responsible for the formation of all cellular blood components) that may 
cause leukopenia and lymphopenia. Furthermore, the increase of the virus load in the 
peripheral monocytes causes severe dysfunction of endothelial cells. In conjunction, 
severe thrombocytopenia  (decreases in the platelets count) and platelet dysfunction, 
associated with the eventual loss of the vascular stability, can occur(34, 35). Thus, 
increasing capillary fragility and gastrointestinal mucosal bleeding will take place, which 
are characteristic of DHF. In addition, severe infection of endothelial cell causes plasma 
leakage, which is characteristic of DSS (13). 
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Figure 4, Represent the route of infection of Dengue virus and the consequence of the 
infection.  Mosquito carry dengue virus will bite the skin of the patient result in the 
transmission of dengue virus particles into the body. The virus will infect immature 
Langerhans cells, which will cause lymphatic spread of the infection and the primary viremia. 
 The virus will then infect other organs and tissues where the virus will replicate into high load 
thus, the secondary viremia will take place and other organs and tissue will be infected 
includes brain, lung and kidney. Miedical virology 
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1.3 Dengue virus genome and virus particles: DENV is a positive single stranded RNA 
virus of Flaviviridae family. The DENVencodes structural and non-structural proteins 
which includes, capsid (C), Precursor membrane (PrM), envelop (E), nonstructural 
protein (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (see figure 5).  DENVcomplex 
has four serotypes (Dengue 1-4) (36). Phylogenetically the four Dengue serotypes are 
distinct and always cluster by themselves within the mosquito borne flaviviruses branch. 
The amino acid sequences of the four serotypes protein are homologous by 63%-68% 
while Dengue 3 and Dengue 1 sequence is more related than the other two serotypes (37) 
(38). The Dengue mature virus particles has smooth outer surface with icosahedral 
scaffold of 90 glycoproteins envelope (E) dimers (39). These 90 E dimers are laid parallel 
to the lipid bilayer of the viral membrane where the E proteins are covering the 
membrane (M) protein completely in the mature virus. The location of the small M 
protein is relative to the overlaying scaffold of E dimers (39). The M protein produced 
during the maturation of Dengue virions in the host cells secretory pathway (discussed 
later) by the cleavage of the precursor membrane (PrM) protein (40). In contrast, the 
outer surface of immature DENV particles are formed with 60 spikes each composed of 
three E monomers surrounding a putative trimer of PrM which cover the protruding 
fusion peptide in E protein (41) (39). In contrast to the external surface, the virus has less-
well-defined inner isomeric nucleocapsid core which formed by the genomic RNA and 
multiple copies of capsid (C) proteins which is surrounded by a host-derived lipid bilayer. 
The positive polarity genomic RNA is about 10.6 Kbp with a 5’ type I cap, unlike the 
cellular mRNA, DENV genomic RNA lack a 3’ polyadenylate tail (see figure 5) (42). 
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Genome encodes a single long open reading frame (ORF) flanked by 5’ and 3’ noncoding 
regions (NCR).  The 5’ and 3’ NCR are about 100 nucleotides (nt) and 700 nucleotides 
(nt) respectively and they play a key role in regulation the replication of the genomic 
RNA and the translation of the ORF (42, 43). The translation of DENV polyprotein is a 
cap dependent and initiated by host cell ribosomal RNA. The large polyprotein will be 
directed into the endoplasmic reticulum to be glycosylated by cellular 
glycosyltransferases and cleavage into 10 proteins by cellular and viral proteases (see 
figure 6). The first proteins to be cleaved are the structural proteins and nonstructural 
protein 1 (NS1) as there are a host cellular peptidase between C/PrM, PrM/E and E/NS1. 
The DENV encodes serine protease will cleavage between NS2A/NS2B, NS2B/NS3, 
NS3/NS4A, NS4A/NS4B and NS4B/NS5. However, the enzyme responsible for cleavage 
between NS1/NS2A is unknown (44, 45). The only structural protein to be released from 
the polyprotein into the cytoplasm is the capsid (C) protein that is a highly basic α-helical 
protein (46). Nascent C (anch C) contains hydrophobic anchor at their c-terminal that 
serves as a signal peptide for endoplasmic reticulum (ER) translocation of PrM and the 
first signal sequence to be translated by cellular ribosomes. This hydrophobic domain is 
cleaved by viral protease to release mature C protein which folded are into compact 
dimer with each monomer containing four α helices (47). These will then bind to the 
genomic RNA and interact with the membrane surface to form the DENV nucleocapsid 
or the viral core. The glycoprotein precursor of M protein contains glycosylation sites at 
the N-terminal region, which is down stream of the hydrophobic signal sequence domain 
of C protein. A cellular protease called signal peptidase will cleavage downstream the 
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signal sequence to release the N-terminal of the PrM protein while the C-terminal has the 
transmembrane domain (TM) act as ER-retention signals to keep the protein associated 
with the ER membrane (4). The major function of the PrM protein is to form a cap to 
cover the fusion loop of the E protein to prevent E from fusion during transit through 
secretary pathway (40). PrM is about 26 KDa present in the surface of immature virions 
which will be cleavage during virus maturation to release the glycosylated,N-terminal Pr 
fragment from the small, membrane anchored M protein which is about 9 KDa and 
function as scaffold to maintain E proteins folded properly.  Envelop protein is Type I 
integral glycoprotein and the major protein in the surface of Dengue virions which is 
about 53 KDa and mediates host cell receptor binding and membrane fusion (48) (4).  
Figure 5, Represent the Dengue virus genome and virus particle. A. the mature  Dengue 
virion is spherical, enveloped virus contains three structure proteins (Capsid, membrane and 
envelop) and RNA genome. The M and E proteins are arranged in the surface of the virion 
where the E protein cover the M protein completely. The ectodomain of E protein composed 
of three structural or functional domains: Domain I is the central domain(Red), Domain II is 
the dimerization domain (yellow) and has the fusion peptide (Green) and Domain III is the 
receptor binding domain (Blue). B. The Dengue virus genome is a single stranded, positive –
sense RNA genome. It is capsidated by 5’-type1 structure and doesn't contain polyadenylated 
3’-tail. The coding region of the genome is divided into structural and nonstructural protein 
and flanked by 3’ and 5’ untraslating regions (UTR). C. The coding regions of the Dengue 
genome are shown which is translated into 3 structural proteins and 7 nonstructural proteins. 
NMR and X-Ray structures are shown for C, PrM, E, NS3 and NS5.    
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The E protein is present in two forms metastable or natural pH conformation and 
low pH conformation in order to have this flexibility to undergo conformational changes. 
E protein has more complex structure compared to the C and M protein (48). E protein 
monomer is structurally divided into a two-helix transmembrane region, which is about 
50 a.a and also called “steam” and elongated ectodomain . The steam is responsible for 
attaching the C-terminal of the E protein into the ER membrane while upstream of the n-
terminal will be cleaved by signal peptidase (49, 50). E protein, lacking the steam region, 
will be released from the ER membrane and is called soluble form of E protein (sE). The 
ectodomain has three domains that are joint by flexible junction that are capable of hinge-
like motion that are important for the conformational changes of E protein during virions  
maturation and fusion of the target cell membrane. Each domain carries out certain 
function, Domain I (DI) is flanked by DII and DIII and composed of eight-stranded β-
sheet which participate in the conformational changes induced during viral fusion (39, 50, 
51). Domain II (DII) contains hydrophobic fusion loop mediates the virus –cell 
membrane fusion at its tip which hidden by the PrM protein the immature virions and by 
a hydrophobic pocket that is supplied by DI and DIII of the second E monomer in the 
dimer interaction on the surface of mature virions (see figure 6). Domain III has an 
immunoglobulin (Ig) like fold and constitute the C-terminal of the E protein ectodomain, 
DIII undergoes a major positional rearrangement during cell entry and is proposed as the 
receptor binding domain (51). Non-structural protein 1 (NS1) is a translocated 
glycoprotein into the ER membrane by the c-terminal signal sequence of E protein and 
cleavage from the E protein by host signal peptidase and cleavage from NS2A by 
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unknown protease. Cleavage NS1 could present in the cell surface in form of highly 
stable homodimers or be secreted into the extracellular space. The function of NS1 is not 
clear yet, NS1 plays a role in the DENV RNA replication as it was demonstrated that 
introducing mutation to NS1 lead to dramatic defects in RNA replication(52). In addition,  
NS1 play a key role in the immunopathogenesis of DENV. The function of the non-
structural protein 2A(NS2A) is not clear however, there is some evidence that NS2A can 
act as an interferon (IFN) antagonist and assist the DENV evasion of interferon inhibition 
of viral replication (53). One of the most important non-structural proteins is NS3 which  
carry out multifunction includes serine like protease activity, RNA helicase- NTPase and 
RTPase (54). The N-terminal of the NS3 has the protease domain (180 a.a), which 
cleaves the viral protein at multiple sites (see figure 6, discussed above).  
Figure 6, Represent the membrane topology of Dengue virus polyprotein. The viral RNA 
is translated as a polyprotein and processed by cellular and viral proteases (represented by 
arrows with different colors). The structure proteins are released from the poly proteins by 
signalase cleavage in the ER.  The PrM and E proteins remain anchored in the lumen side of 
the ER membrane and the C protein remain anchored in the cytoplasm side of the ER where it 
will be cleavage later by the NS2b/NS3 protease. The nonstructural proteins are released from 
the ployprotein by NS2B/NS3 protease in the cytoplasm with exception of NS1 which 
cleavage by unknown protease on its c-terminal. The C, NS1, NS3 and NS5/NS4Bwill be 
disassociate from the ER membrane while the other protein will be membrane anchored. Cell 
(4) 
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The protease activity of the NS3 is dependent on the presence of the co-factor 
NS2B which will form an NS2B-NS3 serine protease complex (45). The cofactor NS2B 
warps around the protease domain of NS3 in a belt-like structure and anchored its 
hydrophobic region into the ER membrane to bring the protease domain close the 
transmembrane domain that must be cleaved within the polyprotein (38) . The C-terminal 
region of the NS3 protein has nucleic acid modifying activates which are essential for the 
Viral RNA replication.  RNA helicase-NTPase is an enzyme has RNA-stimulated 
nucleoside triphosphatase (NTPase) activity and RNA unwinding activity. The helicase-
NTPase domain is composed of three subdomains, where two of them represent the 
NTPase activity and the third part carry out the RNA unwinding activity . NS3 C-
terminal encodes an RNA triphosphatase activity (RTPase) responsible for 
dephosphorylate the 5’end of the viral RNA before cap addition . NS4A and NSB are 
small hydrophobic proteins which act as antagonist to block type I INF signaling 
pathways that are essential to enhance the DENV replication (53). The largest (104KDa) 
and the most conserved protein among Dengue serotypes is the non-structural NS5 
protein. NS5 is a multifunctional protein with methyltransferase (MTase) and RNA 
dependent-RNA polymerase (RdRP) activities (55). The N-terminal of the NS3 protein 
has the MTase domain, which involves in the modification of the Viral RNA 5’ cap. The 
C-terminal of NS5 contains the RdRp essential for the RNA replication. In addition to its 
role in the RNA replication, NS5 has the ability to block the signaling pathways of type I 
interferon to enhance the viral replication and infectivity (56, 57).   
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1.4 Dengue virus infectious cycle: The basic stages of the DENV life cycle include; 
attachment to cell surface, internalization into the host cell, releasing of the nucleocapsid 
and transfer of RNA into cytoplasm, translation of the viral protein, replication of 
genomic RNA, assembly and maturation of the virions, and ultimately the release of 
mature viruses from the cells (see figure7)(36, 40). The early stages in the DENV life 
cycle involve the viral entry, which is mediated by receptor recognition and attachment 
(see figure 7 a.1). E glycoprotein is responsible for the receptor recognition and 
attachment to concentrate the virions in the surface of host cells. The recognition of virus 
–specific cell receptor contributes to host range and tissue tropism (the tissues where the 
virus can replicate) (36). DENV has a wide range of tissue tropism and host range of 
human and mosquitoes that is why it is unclear to determine the virus’s specific cell 
receptor is unclear.  Dendritic cells have a surface protein called DC-SIGN (Dendritic 
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) that is the 
putative primary protein receptor for DENV (58, 59). The attachment and the 
concentration of the virus particles on the surface of the host cells is mainly mediated by 
the domain III of E protein (60-62). However, there is a differential receptor usage by the 
four Dengue serotypes. For instance, DENV-1 specific binding protein on human liver 
cells is the 37/67KDa high-affinity laminin receptor (63), while the GRP78 glucose-
regulated protein has been identified as a receptor for DENV-2 internalization into human 
liver cells (64, 65). The glycosylation pattern on the viral surface varies among different 
Dengue serotypes that can explain the differential receptor usage among these serotypes. 
In addition to the viral factors, cell factors such as heat sock protein associated with 
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membrane micro-domains or lipid rafts can participate in DENV entry as a receptor 
complex which includes Hsp90 and Hsp70 in human monocytes and macrophages as well 
as gp45 and 74 KDa proteins in mosquito cells (66, 67). The internalization of DENV 
into the host cells happen by receptor-mediated endocytosis (RME), also called clathrin-
dependent endocytosis, is a process by which cells internalize (endocytosis) the virus 
particles by the inward budding of plasma membrane vesicles containing the E proteins 
attachment with surface receptor (see figure 7 a.2) (68, 69). The plasma membrane 
vesicles bud into the cytoplasm and deliver the virus particle to early endosomes. Early 
endosomes mature in several ways to form late endosomes as they become increasingly 
acidic at which the virus fusion occurs (see figure 7.b). Flaviviruses are considered 
important models for studying viral membrane fusion as they exhibit the most efficient 
and the fastest fusion machinery of all enveloped viruses (48). DENV membrane fusion 
is mediated by a class II viral fusion protein, the major enveloped protein E has 
hydrophobic sequence represent the fusion peptide which mediate the fusion of the viral 
lipid membrane with the endosome lipid membrane (70). The initiation of the fusion 
processes depend on some factors that include: acidic pH, lipid compassion of the target 
membrane, and histidine residues in the E protein (48). 
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Figure 7, ( Previous page) Schematic representation of the proposed steps of Dengue virus 
life cycle: a. Attachment and receptor mediate endocytosis of the mature Dengue virion. 
Color codes; Dengue virus nucleocapsid is colored gray , Dengue virus E protein DI, DII and 
DIII are colored red, yellow and blue, respectively and the transmembrane domain is colored 
green. The outer/inner leaflets of the viral lipid membrane and the host cell membrane are 
colored yellow/blue and gray/red. The target cell receptor is colored orang. a.1. shown the 
attachment of the virion to specific cell receptor. The surface of the mature virion formed by 
90 homo-dimers of E protein in a metastable form where the D III of E protein will attach to 
the receptor. a.2. show the internalization of Dengue virion into the host cell by receptor 
mediated endocytosis (RME) where the cell internalize the virus by inward budding of plasma 
membrane. b.pH dependent fusion of the virus membrane with the endosome membrane 
and the releasing of the virus nucleocapsid. Color codes; the same as part a of this part, 
Fusion peptide at the distal end of DII is indicated in orange. b.1. low endosomal pH induce 
the outward extension the steam region, followed by the dissociation of E dimers into 
monomer ,expose the fusion loop and the interaction of the fusion loop with the endosomal 
target membrane. b.2. the formation of E trimer and the protonation of histidine residues 
induce the back-folding of DIII and Zipping-up of the steam. b.3. Hemi-fusion intermediate 
the formation of fusion pore by mixing the outer leaflets of the virus and the endosome 
membrane. b.4. generation of the final post-fusion structure (E trimer and the back-folding of 
E protein DIII and zipping up the steam) and opening of fusion pore. b.5. the pore in the virus 
and endosome membrane allow the releasing of the nucleocapsid includes the core protein and 
the genomic RNA which will be transfer into the cytoplasm where it will be in a close contact 
with the ER. c.Translation and replication of the genomic RNA. The translated polyprotein 
is directed into The ER while it is attached to the ribosomes. The RNA dependent RNA 
polymerase will be released from the polyprotein which will carry out the replication of the 
genomic RNA in the cytoplasm in close contact with ER.  Some of the protein will be released 
from the polyprotein and the ER and the rest will be membrane anchored in the ER (for details 
see figure #). d.virus assembly in the ER and maturation in the TGN. d.1. Virus assembly 
takes place when there are enough envelop protein displayed in membrane of the ER where 
the E protein exists as heterodimer with PrM, viral protein then  and the nucleic acid combine 
to form virus particles which will gain lipid membrane by biding from the ER. d.2. After 
assembly the immature virions transit from the ER to the Golgi network where the virions 
encounter a natural pH. The immature virions under a natural pH have a spiky surface. The 
arrangement of the E protein (gray) in 60 trimeric of heterodimer with PrM protein (Pr peptide 
represented by blue color), which extend away from the virions surface gave the virions the 
spiky surface morphology. d.3. during transportation through Trans Golgi Network (TGN) the 
virions encounter acidic pH which initiated conformational changes of the surface proteins. 
The PrM-E heterodimers dissociate from their trimeric spike like organization and form 90 
dimers that lie flat against the virus surface. d.4.the maturation of the virions include cleavage 
of the Pr peptide by cellular furin protease where the Pr peptide maintains its position as a cap 
of E protein(Pr+M-E) as the virions transit through TGN and cellular secretory pathways. e. 
Mature virus releasing. Following furin cleavage, the mature virions is secreted is secreted 
into extracellular space and the Pr peptide is released from the mature particle where the E 
proteins remain as 90 homodimers lying parallel to the virions surface and M protein is 
beneath the E protein shell and embedded in to the viral membrane.   
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The acidic environment on the late endosomes is the key activator of the E protein 
fusion activity that is known as pH dependent fusion. The pH of 6.6 and lower is suitable 
to activate the fusion process. However, the exposure of the virus alone to acidic pH 
result in inactivation of its fusion ability, which suggests that lipid membrane, plays a role 
in the fusion activity of DENV E protein(48). 
The lipid composition of endosome membrane influence the fusion efficiency, for 
instance, cholesterol –rich lipids rafts can enhance the internalization and the fusion of 
DENV (71). Viral factor can also contribute in the initiation of the fusion, as the histidine 
residues in the DENV E protein act as sensors of pH that trigger conformational changes 
in the E protein (72). At natural pH the histidine residues are un-charged but at the acidic 
pH they became positively charged by the addition of extra protons. The protonation of 
histidine residues could release D III of E protein to permit folding-back conformation 
and hairpin formation that is necessary for the formation of fusion pour (72). Up on the 
endocytosis of DENV, the pre-fusion E protein at a natural pH is on its metastable state of 
homodimers parallel to the lipid membrane of the DENV. One of the requirements of 
endosome trafficking and maturation in the living cells is generating an acidic 
environment inside the endosome vesicles (48). Once the pH riches 6.6 or lower, the 
protonation of the histidine residues on the E protein takes place (73). Which trigger the 
E protein to undergo conformational and positional transformation by the outward 
extension of the stream region, accompanied by the dissociation of E dimer into 
monomer (see figure 7 b.1) (74). The dissociation of E homodimer results in the exposure 
of the hydrophobic fusion loop. As a consequence of all these motions, the fusion loop 
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will interact with the lipid membrane of the endosome. In order to establish a close 
positioning with target membrane, the viral E protein arranges in a timers where the E 
monomers are parallel to one another and perpendicular to the target membrane (72). The 
fusion loops are exposed on one end of the timer (figure7 b.2). The DIII of the E protein 
undergoes major conformational changes where it folds back to bring the steam sequence 
in the viral envelop to be in close contact to the fusion loop in the tip of the DII (75). As a 
consequence, the viral membrane will be very close to the target membrane and a hemi -
fusion intermediate the formation of fusion pour by mixing the outer leaflets of the viral 
and target membranes (figure 7 b.3) (76). Finally the fusion pour formed and maintained 
because of the back-folding of E protein DIII and the zipping up of the steam region 
(figure 7 b.4) (72). The fusion pour in the endosome membrane allow the release of the 
nucleocapsid into the cytoplasm. Then the RNA is transferred into cytoplasm to be 
replicated (figure7 b.5). Initially, the released viral RNA is translated into a polyprotein, 
which then is directed into the endoplasmic reticulum (ER) (figure 7 c.). Signal sequence 
within the poly protein translocate the E, PrM and NS1 protein into the lumen of the ER, 
while the C protein, NS3 and NS5 are released into the cytoplasm (72). The process of 
this polyprotein releases the NS5 that contains the RNA dependent RNA polymerase 
(RdRp), which must happen before the RNA replication. Genomic RNA replication 
begins with the synthesis of a genome-length minus stranded RNA, which then serve as a 
template for the synthesis of additional plus stranded RNA(77). The viral RNA 
replication is asymmetric where the positive strands accumulate ten times more than the 
minus strands (78). Virus assembly takes place once there is enough envelop protein 
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displayed in the membrane of the ER (figure 7d.1). The assembly occurs in the ER when 
the newly synthesized viral protein and nucleic acid combine to form immature –fusion-
incompetent virus particles (78). After assembling, the virions transit from the ER 
through trans-Golgi network (TGN) to the cell surface. Budding assembles the virions 
from the ER, which is responsible for the gain of host derived lipid envelope. Through 
this trip the immature virions undergo a protease- and pH- dependent maturation (79, 80). 
During the maturation, E proteins go through positional reorganization, while the PrM 
protein is cleaved by cellular furin protease. The conformational changes in E protein are 
triggered by the low pH in the exocytosis vesicles and occur before the cleavage of the Pr 
peptide by the furin protease (81). The structural change from the immature virions with 
spiky surface to mature virions with smooth surface occurs during transportation through 
the TGN (figure7, d.2 and d.3).  The initial bud of immature virion into the ER happen 
under a natural pH environment where the E protein form a 60 trimeric spikes that 
extends away from the surface of the virions where the “ Pr ” peptide cover each E 
monomer (figure 7,d.1). During its transit through the secretory pathways, the virions 
encounter acidic pH in the TGN. Under the acidic condition the PrM-E protein 
heterodimer disassociate from the trimeric spike- like organization to form dimers of 
PrM- E protein which lie flat against the viral surface, forming the 90 dimers envelop 
shell of DENV. This rearrangement of E protein gives the virions its smooth surface 
morphology (figure7 d.3) (39, 60). As the virions transit through the TNG, The cellular 
furin protease cleavages the glycosylated-N-terminal Pr peptide from the small- 
membrane anchored M protein that will remain associated with the virions. However, the 
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cleaved Pr peptides remain in its position as a cap on E protein during the trafficking in 
the TNG (figure7, d.4) (60). Once the virions are released to the extracellular space the Pr 
peptide will be released and the virions will be on its mature, infectious form where the E 
protein arranged in a 90 homodimer lies against the virus membrane and completely 
cover the small M protein (figure7,e.). An interesting aspect of the DENV life cycle is the 
generation of subviral particles that contains only the PrM and E protein that are 
associated with the lipid membrane without the nucleocapsid. These particles can be 
presented as natural by-product in the supernatants of infected cells. These particles are 
slightly less dense than the virions, they are 30 nm in diameter and are called 
recombinant subviral particle (RSP) (36, 60). 
1.4. IMMUNE RESPONSE: Immunity is the collective and coordinated actions taken 
by cells and molecules of the immune response toward a foreign substance such as a viral 
infection. Immunity has two lines of defense early defense called innate immunity 
(known as native immunity as well) and late immunity called adaptive immunity. Each 
defense line has its own cells and molecules. Different effector cells mediate innate 
immunity such as phagocytic cells, which recognize the microbial substance or the 
antigen (Ag) at the site of infection, ingest and destruct the ingested microbe. Phagocytic 
cells include macrophages and dendritic cells which play a key role in linking innate and 
adaptive immunity by presenting the antigen to adaptive immunity cells. Granulocytes 
have inflammatory granules in their cytoplasm and are composed of three types: 
neutrophils, eosinophils and basophils(82). Natural killer cells (NK) are bone marrow 
derived lymphocytes which mediate cytolysis of virus infected cells to clear the viral 
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infection. Cytokines are a large and heterogeneous group of secreted proteins produced 
by many different cells of innate immunity and adaptive immunity later on. Cytokines 
have different categories depending on their biological actions.   
Proinflamatory cytokines are secreted proteins that promote activation of immunity cells 
and they include, α-Interferon (INFα), β-Interferon (INFβ), tumoral necrosis factor 
(TNFα), IL6, IL2 and INF-δ.  Chemokines are secreted proteins that act as chemo 
attractants to recruit immune cells to the site of infection such as CXCL-8, CXCL-3 and 
CXCL-1. Complement proteins are a group of more than 30 different plasma proteins that 
interact with each other and bind with the pathogen to kill the pathogen. Adaptive 
immunity is composed of the humoral and cellular immune response. Antibodies are Y 
shape proteins where the two arms of the antibodies recognize identical antigen sites. 
Antibodies are secreted by lymphocytes cells called B-lymphocytes which secret Ab to 
the extracellular space or display the Ab on their surface (82, 83). Cell mediated 
immunity (also known as cellular immunity) is mediated by T-lymphocyte cells which 
divide into two major categories: Helper T-lymphocytes (Th) and Cytotoxic T-
lymphocytes (CTL). They have different effector functions and different surface markers. 
Helper T-lymphocytes carry a surface protein called CD4 and have at least four main 
types of CD4+ effector T-cells called Th1, Th2, Th17 and follicular helper T-cells (Tfh). 
Each one of these subclasses promotes different immune responses depending on the type 
of infection. Cytotoxic T-lymphocytes carry a surface protein called CD8 and are 
responsible for killing infected cells that display the antigen on their surface. Innate and 
adaptive Immune cells are localized and generated from anatomically identified tissues 
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and organs. Lymphoid tissues and organs divide into two major types: Central (primary) 
lymphoid is the generative organs and tissues and the Peripheral (secondary) lymphoid is 
the site where antigens present to the naïve immune cells in order to be activated. 
Includes spleen and lymphoid nodes that distribute around the body and are connected 
through the lymphatic system where the immune cells and molecules are circulated in a 
resting state until they get activated (82, 83).  
1.4.1. Innate immune response against dengue virus infection has two phases; the 
immediate phase of inhibition of DENV infection by type I Interferon pathway and early 
phase of elimination of DENV infection by NK cell-mediate killing of infected cells.  
One of the most remarkable pathways of host cell defense to limit the viral infection is 
type I interferon system. A few hours after the initial bite of an infected mosquito and 
prior to recruitment of other immune cells the Interferon response will be activated (see 
figure 8) (84, 85). Type I interferon is induced by almost any type of cells in response to 
DENV infection but some cells seems to be specialized for the task. These are immature 
dendritic cells (Langerhans cells), which are considered the first innate immune cells to 
be infected with DENV (see figure 8). There is two classes of antiviral type I interferon: 
INF-α and INF-β that are induced by cytoplasmic sensors of Dengue viral RNA, RIG-I 
(retinoic acid inducible gene 1) and MDA-5 (Melanoma Differentiation – Associated 
protein-5) in the cytoplasm of infected cells will trigger also the secretion of type 
interferon upon recognition of RNA motifs (86). Production of INF-α/β will affect the 
infected and uninfected cells, as they will bind to interferon receptors in the surface of 
these cells. The interferon receptors will activate intercellular cell signaling pathways that 
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aim to stimulate the transcription of more than 100 different genes with antiviral 
activities. One such protein is the dsRNA–dependent protein kinase called PKR that 
inhibits the translation of the viral protein and inhibits viral replication (87). However, 
DENV has evolved mechanisms to escape from the interferon response. These 
mechanisms are the inhibition of both the production and signaling of type I INF. Non-
structural proteins NS2A to NS5 responsible for DENV evasion (86). For instance, the 
NS2B3 protease complex functions as an antagonist to block the INF receptors.  NS2A, 
Figure 8. Represent the Initiation of immune response after the inoculation of DENV by 
mosquito pit. Infection by dengue virus (DENV) occur after subcutaneous injection of the 
virus into the skin. Released Dengue viral particles may infect nearby cells (thought to be 
predominantly Langerhans cell or dendritic cells (iDCs)). The infection of iDC activates 
resident immune cells includes granulocytes such as mast cells which will initiate 
inflammatory response. A local inflammatory response to DENV in the skin prompts the 
recruitment of leukocytes from the vasculature, including natural killer (NK) cells and T cells, 
which promote the killing of virus-infected cells at the site of injection. At the main time, 
infected dendritic cells and macrophages travel to draining lymph nodes via lymphatic vessels 
to establish systemic infection as described in FIG 4. Nature Reviews(3) 
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NS4A, NS4B and NS5 function as antagonists of type I IFN signaling by targeting 
different components of the signaling pathways. INF-α/β play an important role in the 
mechanisms of host defense against DENV but, once the viral replication has been 
established the INF system has little effect on DENV. At the same time, DENV 
replications in immature dendritic cells (Langerhans cells) are facilitated by the 
internalization of DENV through the adhesion of the E protein with cellular receptor such 
as Dendritic Cell-Specific Intracellular adhesion molecule-3-Grabbing Non-integrin (DC-
SIGN) (see figure 8) (59, 88). It has been observed that a dramatic inhibition of DENV 
infection happens by blockade of DC-SIGN receptors, thus DCs play a central role in the 
establishment of DENV infection and stimulation of a strong immune response. The 
normal function of the Langerhans cells is to capture antigens and process them into 
immunogenic peptides, migrate from the site of infection to the nearby lymph node to 
present the antigen to other lymphocytes. Inside the Langerhans endosomes there are 
sensors called Toll Like Receptors (TLR), which recognize DENV ligands, derived from 
its life cycle. TLR molecules are conserved proteins and there is 11 types of TLR that 
have been identified in humans.  TLR molecules that involve in DENV recognition are 
TLR 7, TLR 8 and TLR 9 (89, 90). They trigger the production of cytokines such as IL-2, 
IL-12, IL-6, TNFα, and INFα/β. All this cytokines set up a state of inflammation in the 
tissue that is associated to dilation of local blood vessels and changes in the endothelial 
cells of their wall. These changes happen prior to the recruitment of other immune cells 
and lead to the movement of leukocytes such as neutrophils and monocytes out of the 
blood vessel and into the infected tissue. The blood vessels become more permeable 
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which will facilitate the migration of other leukocytes and lymphocytes to the site of 
infection (see figure 8).   Once the monocytes migrate into the tissue they will 
differentiate into macrophages.  Neutrophils, non-infected Langerhans and macrophages 
will recognize, ingest and destroy DENV, which present in the extracellular space. 
Activated macrophages and Langerhans cells will secret cytokines such as IL1-β which 
activates lymphocytes and increase access of effector cells, TNF-α which increase 
vascular permeability which lead to an increase in the entry of plasma proteins and cells 
and fluid drainage to lymph node, CXCL8 which is a chemotactic factor that recruits 
Natural killer (NK) to the site of infection (91). Since, DENV is an obligated intracellular 
parasites. Natural killer cell-mediated killing of infected cells clears the infection at this 
early phase( see figure 8). Gathering of NK cells and Langerhans (iDC) in the inflamed 
tissue result is physical contact between NK and Langerhans (iDC) which promotes 
events including, Langerhans (iDC)- induce NK proliferation, NK-mediated shattering of 
Langerhans (iDC) and NK-dependent Langerhans maturation (92). The conversation 
between NK and iDC promotes the quality and the intensity of innate response and 
activates appropriate adaptive response against DENV infection. iDC releases cytokines 
such as IL-12 and IL-2 which induce the proliferation and activation of NK by releasing 
cytokines like IFN-δ and TNFα. Those cytokines will induce the maturation of 
Langerhans (iDC) to the mature form of dendritic cells that are characterized by special 
surface marker which will migrate to the lymph node. Mature DC releases type I 
interferon that increase the cytotoxicity of NK to mediate killing of infected cells 
including infected Langerhans cells (iDC). NK-mediated shattering of Langerhans (iDC) 
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as it expresses DENV antigen on its surface as infected cells which stimulated NK to 
destroy it order to prevent the spread of the infection to other lymphocytes in the lymph 
node. At this point, dendritic cells and macrophages will migrate to the lymph node for 
subsequent presentation of DENV antigen to naïve T and B-lymphocytes to activate the 
adaptive immune response (92).                                                                                                                       
1.4.2. Adaptive immune response against dengue virus infection has two goals: The 
blocking of the viral entry by antibodies secreted by B-lymphocytes OR elimination of 
infected cells by Cytotoxic T-lymphocytes. Naïve lymphocytes are normally circulating 
throughout the body in a “resting” state. Once they become encounter with DENV Ag 
from APC (i.e., macrophages and dendritic cells) a series of events will take place; 1-
Lymphocytes activation, 2- clonal expansion or multiplication of lymphocytes, 3- 
differentiation into either effector lymphocytes or memory lymphocytes, and 4-migration 
from the lymph node to the site of the infected tissue (3). Cellular immune response 
mediated by CD4+ and CD8+ T-cells are activated in the lymphocyte through Antigen 
presentation. T-lymphocytes have a special cell marker called T cell Receptor (TCR). 
This receptor is responsible for recognizing the Ag. Both CD4 and CD8 used TCR to 
recognize the Ag but each cell required a different ways of antigen presentation (93). 
When the virus enters the cells and start to synthesis their proteins, the newly synthesized 
viral protein will be presented through either MHC class I or MHC class II presentation 
pathways. MHC molecule has a binding groove where the Ag will be bound and 
presented to TCR on the cell surface (see figure 9). MHC class I molecules present 
DENV antigen to CD8+ T-cells while MHC class II molecules  present DENV antigen to 
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CD4+ T-cells (3). Both MHC class I and III are displayed on the surface of APC . MHC 
class I present in almost all nucleated cells. TCR has the affinity to bind to specific 
DENV Ag epitopes where it recognizes antigen epitopes throughout DENV polyprotein, 
however the most recognized Ag epitopes present in the NS3 protein (94). DENV 
specific T-cells display different effector functions including; targeting cell lysis and 
production of a range of cytokines. 
Figure 9, Represention the pathways of DENV antigen representation to effector T 
cells and T cell responses to DENV proteins, the dengue virus life cycle and sources of 
antigen are show. Viral attachment, internalization, fusion and translation proceed as 
described in FIG 7. Newly synthesized viral proteins enter MHC class I or II presentation 
pathways and viral peptide epitopes are presented on the cell surface within the binding 
groove of MHC molecules. MHC class I present DENV antigen peptide to the CD8+ T-
cells which response by lysis target cell. MHC class II present DENV antigen peptide to 
CD4+ T-cells which response by cytokines secretion. Both CD8+ and CD4+ T-cells bind 
to the peptides, which match the epitopes of their T-cell receptor (TCR). Nature Reviews 
Immunology(3) 
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Effector Functions of DENV specific CD4+ T-cells (Th): a broad range of 
cytokines is produced by the helper T-cells (Th) in response to recognition of DENV 
antigen peptide-MHC complex on the surface of macrophage and dendritic cells. The 
pattern of cytokines production follows certain sub-classes of T-helper cells called T-
helper 1 (Th1) includes INF-δ, IL2 and TNFα. The principal stimulation of Th1 cells is 
the intracellular microbes such as DENV. Th1 effector functions include; 1-activation of 
macrophage to ingest and destroy DENV, 2-activation of B-cells to secret DENV specific 
antibodies, 3- immune response amplification (93). The signature cytokines of Th1 is 
IFN-δ, which is a principal macrophage activating cytokines. Once macrophages are 
activated by INF-δ they will produce molecules such as reactive oxygen, nitric oxide and 
increases the production of lysosomal enzymes, which increase the phagocytosis of 
DENV and enhance the killing of ingested viruses (95). Activated macrophages secrete 
cytokines required for Th1 differentiation such as IL1, IL12 and TNFα, which also recruit 
leukocytes and promote inflammations. INF-δ secreted by Th1 stimulates B-cells to 
secrete antibodies. In addition, IL-2 and TNFα secreted by Th1 promote the 
differentiation of CD4+T-cells to Th1 subclass and inhibit the other T-helper subclasses 
such as Th2 and Th17 in a process called amplification of immune response (3, 96, 97).  
Effector function of Dengue specific CD8+ T-cells (CTL): Elimination of DENV 
infected cells by cytotoxic mediated killing of the cells. CTL recognize DENV antigen 
epitope-MHC class I complex on the surface of infected cells where the CTL will be 
activated to secrete cytotoxic proteins including granzymes and perforin which induce 
cell apoptosis by cleave cellular proteins such proteins are stored within cytoplasmic 
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granules in the CTL. Once the cytotoxic ability of CTL is activated a series of events take 
place on the cytoplasm of the CTL; 1- microtubule in cytoplasm of CTL moves the 
cytoplasmic granules to be concentrated in the region of contact with infected cells, 2-
granules will fuse with the plasma membrane of CTL at the site of connection with the 
infected cell. 3-exocytosis of CTL’s granules and detachment of CTL from infected cells. 
The death of the infected cells occurs during the next 2 hours and happens even if the 
CTL detaches (93, 97-99). 
Humoral response against DENV is mediated by secreted antibodies, which are 
produced by B-lymphocytes. Resting naïve B-cells have either IgM or IgD 
immunoglobulin on its surface that will be used to recognize DENV antigen through the 
process of antigen presentation on the lymph node that called the recognition phase. The 
proliferation and differentiation of B-cells depend on the stimulation of T-helper cells.  
The antibody responses to DENV antigen require that the antigen be recognized and 
internalized by B-cell and that peptide of DENV antigen should be presented to the T-
helper cells at the lymph node that will stimulate the B-cell to enter the activation phase 
(100). During that phase, B-cells specific to that antigen peptide will be multiplied 
through the clonal expansion process and then will be differentiated either to memory B-
cells or to Plasma cells which will secrete antibodies.  The activation of B-cells by T-
helper cells, known as helper T-cells dependent antibody response, mainly happens in 
response to protein antigen such as DENV proteins antigens (3). Once the B-cells are 
activated by T-helper-cells their surface marker will be changed through a process called 
isotopes switching (3) (100, 101). As was mentioned earlier, DENV infection activated 
32 
 
the pathways of Th1 cells that promote the heavy chain isotype switching to IgG instead 
of IgM and IgD. The secreted Ig main function is mediated by binding to the antigen 
through the epitopes of the light chain, but also to different effector cells. Thus, Th1 
promotes isotype switching to IgG to clear DENV infection. Antibodies will be secreted 
from plasma cells at lymph node and migrate to perform its effector functions at the site 
of infection (102).         
                                  
Figure 10, Represent the mechanisms of neutralization and enhancement by dengue 
virus-specific antibodies, A. At high levels of epitopes occupancy, dengue specific antibodies 
can block the fusion at a post-binding stage or after the viral entry to prevent the release of the 
virus particles from the endosomes. B. At high levels of epitopes occupancy, dengue specific 
antibodies can block the binding of virus particles and inhibit the viral entry. C. At low levels 
of epitopes occupancy, dengue specific antibodies can enhance the uptake of virus particles in 
to cells by the interaction between the Fc receptor on the surface of host cell and the heavy 
chain of the IgG in a phenomenon called “antibody dependent enhancement” of the disease. 
Nature Reviews Immunology(3) 
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Effector functions of Dengue virus specific antibodies: Includes neutralization of 
DENV (the most direct way to protect host against DENV infection by binding to the 
viral envelope proteins and prevent it from entry of host cells). Opsonization is the 
coating of DENV by antibodies and subsequent phagocytosis of DENV, complement 
activation against DENV and antibody-dependent cellular cytotoxicity (see figure 10) 
(103). The main targets of antibody responses to DENV are the precursor membrane 
(PrM), envelope (E) structure protein and non-structural protein 1 (NS1) (100, 104). 
DENV E glycoprotein is the main surface component of the virus particles and has the 
most extensive antibody response. E protein domain III contains the putative receptor-
binding site, which is the binding region that allows the virus to attach to the target cells. 
That makes Domain III the most accessible part of E protein and the most variable in 
amino acid sequence between serotypes (104). Antibodies specific for domain III are 
highly specialized among serotypes. However, they consist a small fraction of the total 
antibody in immune sera binding to DENV as it was demonstrated by a study that 
neutralized DENV by human immune sera (103, 105). This study proposed that 
antibodies directed to other epitopes are responsible for the most of neutralizing of 
DENV. M protein is completely hidden by the E protein dimers and is in the mature 
virions. In some cases, an incomplete cleavage of the PrM results in partial mature or 
immature virions to be released from the cells where the anti-PrM antibodies will 
recognize the glycoprotein in the surface of the virions. NS1 protein is produced as an 
extracellular protein or presents on the surface of infected cells, thus the antibodies 
against NS1 do not play a role in neutralizing of DENV but has a central role in antibody-
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dependent cellular cytotoxicity (100). Natural killer (NK) cell has a surface molecules 
caller FcδR III which is a receptor for IgG where the NK binds to the heavy chain of the 
anti NS1 IgG which cover DENV infected cells in a process called antibody-dependent 
cellular cytotoxicity (ADCC) (see figure 10) (3). The NK is activated to kill the antibody-
coated cells. The main function of anti-E antibodies is to neutralize and eliminate DENV. 
Anti-E antibodies bind to E glycoprotein and block the ability of DENV to attach or to 
enter the target cells. The antigen binding regions of these antibodies are highly 
specialized to recognize a certain amino acid sequence. These are known as monoclonal 
antibodies and they are different among different DENV serotypes (103). Antibodies 
against PrM and E protein mediate opsonization and phagocytosis of DENV. 
Macrophages have a surface protein called FcδR I that is a receptor for IgG. The anti-E 
coat the surface of Dengue mature virions and anti-PrM coat the surface of immature 
Dengue virions. The heavy chain of those IgG antibodies may bind to the FcδR I receptor 
on the surface of the macrophages and activate the macrophages to ingest and destroy 
antibodies coated (opsonized) Dengue virions. Anti-PrM and E protein coated the 
Dengue virions activate the complement system to eliminate the virus from the 
extracellular space (106) (100, 107). Complement system composed of plasma proteins 
that bind to the heavy chain of the antibodies coating the virions. In the case of DENV 
infection, the classical pathway is the most common pathway since IgG is the 
dominating. Classical activation of the complement system is initiated by the binding of 
complement protein 1 (C1) to the heavy chain of anti-E or PrM IgG followed by a 
sequential binding of other complement proteins including C3a and C5a (108, 109). 
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Activation of the complement system results in the following actions; opsonization of 
DENV to macrophages and neutrophils, activation the phagocytosis of the virus, and 
stimulation of inflammatory response as the C5a and C3a protein induce inflammation by 
activating neutrophils, eosinophils and basophils (109). Although these induction of the 
inflammation trigger plasma leakage of endothelial cells which result in unfavorable 
immune response (as it will be discussed) (110, 111).  Adaptive immune response is 
developed during the lifetime of an individual as an adaption to infections with that 
pathogen. Thus, creating a memory of defense against this pathogen in the secondary 
infection is an important role of adaptive immunity known as immunological memory 
which confers lifelong protective immunity. Other non-structural protein such as NS3 and 
NS5 could be also a target of antibodies response but, these antibodies generate a weak 
immune response. The possibility of presenting those antigens (NS3, NS5) to B-cells are 
limited and depend on the lysis of infected cells to release those antigen into the 
extracellular space (3). The main role of vaccination is to generate lifelong protective 
immunity against certain pathogens. Protective immunity against secondary infection of 
DENV is one of the most important consequences of adaptive immunity which depend on 
generating a population of memory lymphocytes which can mediate a long-lived 
immunological memory to generate rapid and strong immune response in the secondary 
infection of DENV infection.  Individuals who have been infected with one dengue 
serotype (Primary DENV infection) have long-term protective immunity against that 
serotype and short-term protection against the other three serotypes of DENV (3). 
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Subsequently, the patient will be in danger to a sever disease after the secondary infection 
of the other three serotypes, known as immunopathogenesis of DENV infection.  
1.5. Immunopathogenesis of Dengue virus secondary infection: Immune response 
against DENV infection has two possible outcomes; protection against infection and 
illness or unfavorable clinical outcomes such as DHF and DSS . The well-established 
finding that there is a high chance of generating severe illness such as DHF and DSS in 
patients with secondary infection of heterotypic Dengue serotypes provides strong 
evidence for pathological side to DENV pre-existing immunity. Protective immune 
responses against one serotype are capable to respond more rapidly than naïve cells 
during the secondary infection of other serotypes (98, 112, 113). However, because of 
sequence diversity between the DENV serotypes, the re-activated immune response 
occurs in the context of serotype cross-reactive immune response. Antibody-dependent 
enhancement of dengue infection can be mediated by anti-E protein antibodies, which 
trigger the uptake of mature DENV by host cells, and anti-PrM antibodies, which trigger 
the uptake of immature or partially mature DENV by host cells. For instance, up on the 
secondary infection of other serotypes the memory B and T cells will be reactivated to 
fight the infection. But these reactivated lymphocytes do not have the optimal degree of 
affinity for the new infecting virus epitopes that result in unfavorable immune response 
or immunopathogenicty. The major factors that are considered to contribute to the DENV 
immunopathogenicty are Anti- Dengue antibodies (114), serotype cross reactive T cells, 
complement activation and soluble factors.  
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Antibodies responses associated with disease, some evidence suggests that 
specific antibodies play a role in the viral pathogenicity (35). Such evidence includes the 
increment of the risk to develop DHF and DSS during primary infection in infants whom 
born to mothers with established immunity to DENV. The tropism of DENV for 
monocytes and dendritic cells, both expressing FcδR receptor for the heavy chain of the 
IgG, creates the opportunity for DENV specific antibodies to enhance the viral entry (see 
figure 10) (115). A phenomena called “antibody- dependent enhancement” (ADE) it 
enhances the disease (116). This phenomenon explains the risk of developing DHF and 
DSS occurred in infants (at age of 6 to 9 month) who were infected with a DENV 
serotype different from that which infected their mothers. The infants receive anti-dengue 
maternal antibodies that declined to sub-neutralizing levels. In that case, the number of 
the antibody molecules bound per dengue virions is below the threshold necessary for  
neutralization (116). Thus, the host cell covered by FcδR receptor will up take the 
virions- antibodies complex more efficient than the entry of the virus through the viral 
specific receptors which result in increasing the viral loads and enhancing the disease 
(35).  
T cell responses associated with disease: activation of the memory T cells with 
higher avidity for the primary infection viral serotype than the new infecting serotype 
generates “cross reactive T cell response” which case tissue damage as a result of 
cytolysis or inflammation induced by the high number of activated memory cells. During 
secondary infection with a heterologous serotype, cross reactive epitope reactivate a large 
number of memory T cells than naïve cells (117). These cross reactive T cells have low 
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avidity to the viral epitope serotype of the secondary infection, which will release 
cytokines such as TNF-α and IL-13 which affect vascular permeability. Soluble factor 
associated with disease, the activation of high numbers of non-protective T cells and the 
high viral load or the enhancement of the disease due to ADE, result in a “storm” of 
inflammatory cytokines and other mediators leading to plasma leakage. The main 
characteristic of DHF/DSS is the plasma leakage that is caused by malfunction of 
vascular endothelial cells induced by cytokines or chemical mediators. The cytokines 
elevated in patients with DHF/DSS includes, TNF-α, IL-2, IL-12and IL-6. OF those 
cytokines TNF-α plays a critical role, there is a positive correlation between TNF-α 
concentration and thrombocytopenia as it can induce endothelial cells apoptosis and 
plasma leakage (23, 111). Complement activation associated with disease, the increment 
of the viral load during the secondary infection results in a high level of secreted NS1 
which will be recognized by cross-reactive antibodies; this complex activated the 
complement specially C3a and C5a which induce plasma leakage. This evidence 
suggested that a balance between the favorable and unfavorable immune response 
determines the outcome of DENV infection. Therefore, there is a high urge to generate 
vaccine alternatives to provide protection against the DENV infection and the 
unfavorable immune response against the virus infection (23).  
1.6. Dengue virus vaccine research and development progress: The first attempt to 
generate Dengue vaccine was in 1945 by A.Sabin who attempted to generate an 
attenuated DENV; the virus was reactogenic caused a rash in human volunteers (9). Till 
now there is no licensed Dengue vaccine in the market due to the challenges of Dengue 
 
39 
 
vaccine development(see table 1). These challenges include the multiple viral serotypes, 
incomplete cross- protection, and the development of ADE, theoretical potential for DHF 
and DSS in vaccinees. In addition to, viral interference and lacking animal model that are 
faithful to human disease. Instead, Dengue vaccine should be free from significant 
reactogenicty and induce long life protection against four Dengue serotypes to avoid 
enhancement of the disease (3).  Currently, there are many dengue vaccine candidates in 
the preclinical and different clinical testing phases (see figure 11 and table 1). Vaccine 
development has fixed stages of testing the new candidates that includes:  Pre-clinical, 
Phase I, II and III. Pre-clinical studies which includes animal model experiments. Clinical 
testing which divided into three phases; Phase I is the first attempt to test the candidate 
vaccine in humans involves a small group of adults (20-80). It aims mainly to verify the 
safety in human. Phase II includes larger group of several hundred individuals. It is 
divided into two sub stages, Phase IIa and Phase IIb. Phase IIa includes groups at risk of 
acquiring the disease and present in the endemic areas. Phase IIb includes groups at low 
or no risk of acquiring the disease. The aims of phase II are to study the candidate 
vaccine’s safety, immunogenicity, proposed doses, schedule of immunizations, and 
method of delivery. Phase III is the last clinical trial and includes larger trials, involving 
thousands to tens of thousands of people in different parts of the world.  To be approved 
and licensed the vaccine should pass a Phase III trial successfully. The vaccine developer 
will submit a Biologics License Application to the FDA. Finally, the candidate vaccine 
may be license to be manufactured. Ideal Dengue vaccine could be a live attenuated virus 
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vaccine or chimeric virus vaccine or an inactivated whole virus, protein subunit vaccine, 
a vectored vaccine or a DNA vaccine.  
Live attenuated vaccine candidates: When passing the virus serial passages in 
tissue culture. The virus will lose its virulence or became less virulence that is known as 
attenuation. Live attenuated virus is a viable virus that can replicate in host cells but is 
less harmful than the wild type virus. Basically, the attenuated virus carries mutations in 
its genome that cause the changing in the virulence of the virus and are not present in the 
wild type virus. Attenuation can be reached by passaging the virus several passages in 
tissue culture or by genetics technique to introduce specific mutations in the viral 
genome. Live attenuated DENV vaccine can induce strong humoral and cellular immune 
responses to both structural and non-structural proteins as it mimics the natural DENV 
infection. Live attenuated virus vaccine is a cost efficient vaccine. It replicates to high 
titer in tissue culture to greater than 107 infectious unit per ml in cell culture, which 
means that 100 ml cell culture can yield nearly 1 million doses of vaccine, as the 
attenuated DENV can infect human at low doses of 103 infectious unit. However, the live 
attenuated DENV vaccine has its own challenges. The replication of a live DENV 
vaccine can develop a significant illness that generates symptoms such as fever, rash, 
headache and pain. The risk of transmissibility by mosquitos should be considered as the 
replicated DENV vaccine can generate high titer viraemia, which is sufficient to initiate 
an infection in the mosquito. Genetic instability of the mutations that confer the 
attenuation phenotype can cause DENV reactogenicity following replication in humans, 
which may lead to development of severe illness. 
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Some of these challenges were solved using the guidelines of Yellow fever live 
attenuated vaccine, such as the doses of the vaccine that generates only low titer viremia 
which reduce the risk of transmissibility by mosquitos and develop asymptomatic or sub-
clinical sign of infection after vaccination (118).  Live attenuated DENVvaccines are 
under development; Walter Reed Army Institute of Research (WRAIR) generated 
attenuated DENV 1,2,3,4 by passages the virus in primary dog kidney (PDK) cells and 
terminal passage in fetal rhesus lung cells. The candidates were passed 20 times in PDK 
cells and the attenuated virus monovalent DENV1-2-3-4 (PDK 20) vaccine candidates 
have been evaluated in rhesus macaques where it induce neutralizing antibodies to clear 
Dengue infection. These monovalent vaccines were tested in phase I trial where DENV2-
3-4 vaccines were mildly reactogenic, but DEN1 retained its reactogenicity and generated 
rush and fever in 40% of the vaccines (119). A the result of phase I, DENV-1 was 
considered under-attenuated and generated excessive immune response and DENV-4 was 
over attenuated and generated poor immune response. Thus, a further passaged DENV-1 
was generated by passage the virus in PDK 27 times and a lower passaged DENV-4 was 
generated by passage the virus in PDK 6 times instead of 20 times. Currently, tetravalent 
formulation composed of DENV-1(PDK27), DENV-3(PDK20), DENV-4(PDK6) and 
DENV2 (PDK53) are in phase II trial in 86 adult volunteers in North America and South 
Asia. DENV-2 was the only exception that was different in phase II from Phase I. As 
DENV-2 was passaged 53 times in PDK cells, the virus was not inducing viremia while 
stimulating robust immune response(120, 121). In order for WRAIR vaccine to pass the 
clinical trials, the mutation contributing to the attenuation phenotype should be identified 
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and show how stable they are (122). The National Institute of Allergy and Infectious 
Diseases (NIAID) used reverse genetic techniques to introduce defined deletion mutation 
in the 3’-untranslated region (UTR) of DENV-1-4 full-length cDNA clones to generated 
attenuating DENV-1-4. The deletion of 30 nucleotides at the 3’ UTR (nt 9,834-9,863) in 
DENV-1-4 generates balance between the level of attenuation and immunogenicity in 
non-human primates and humans but not for DENV2-3. During the phase I trial of 
rDENV-1∆30 and rDENV-4∆30, 28 volunteers were vaccinated with 10(3) plaque-
forming units (PFU) of the attenuated virus which induced neutralizing antibodies by 28 
days post-vaccination. At day 180, 94% of the vaccinees generated neutralizing 
antibodies and generated no symptoms or sub-clinical symptoms. The rest of the 
volunteers received a high dose of 10(5) PFU and generated symptoms including rash 
and increases in liver enzymes. Phase I trial proved the safety of the vaccine, as it 
remained genetically stable following the replication in human, the vireamia titer level 
was low and the virus was not transmitted to mosquito because the ∆30 mutation 
attenuates the virus replication in mosquito (123). As rDENV-2∆30 and rDENV-3∆30 
were not immunogenic in non-human primates, the NIAID used an alternative approach 
to generate suitable vaccine candidates for DENV-2-3. Chimeric virus strategy has been 
used to introduce the membrane precursor (PrM) and E protein of DENV-2 and DENV-3 
into rDENV-4∆30 genetic background to generate the chimeric attenuated DENV-3/4∆30 
and DENV-2/4∆30. The two chimeric attenuated viruses and the two attenuated viruses 
have been combined to generate a tetravalent DENV vaccine formulation (TetraVax-
DV). TetraVax-DV induce neutralizing antibodies in rhesus monkeys and was used to 
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immunize volunteers in phase I clinical trial. Acambis and Sanofi Pasteur generated a 
chimeric DENV vaccine using the Chimervax platform. Acambis substituted the genes of 
the PrM and E protein from each of the four Dengue serotypes into the live attenuated 
YF17D vaccine strain (124). The four separated functional chimeric virus were used as 
monovalent vaccine candidates and passed the phase I trial. The trail proves that the 
monovalent vaccines are safe, as they induce low titer vireamia, generates sub-clinical 
symptoms and are noninfectious to mosquitos (124). The four chimeric viruses are then 
combined to generate a tetravalent chimeric DENV vaccine, which induce a high level of 
neutralizing antibody in monkeys. The phase I testing of ChimeriVax tetravalent vaccine 
was safe without any serious adverse side effect and immunogenic. However, a phase IIb 
clinical trial showed poor efficiency as the vaccine doses generate protection against 
DENV-1-3-4 but not DEN2, which negatively impacted the overall protection. 
ChimeriVax is the most advanced vaccine candidate to be tested in humans. The Center 
for Disease Control and protection (CDC) in the US used the attenuated DENV-2 PDK-
53 developed by Mahidol University to generate a set of chimeric DENV vaccine 
candidates by substituting E protein from DEN-1-3-4 into the live attenuated DENV-2 
PDK-53 vaccine strain (125). The preclinical studies of the tetravalent formulation 
(DENVvax) were safe and immunogenic in monkeys, which make the DENvax moved to 
Phase I clinical trial. The previous success of inactivated tick born encephalitis and 
Japanese encephalitis virus vaccine encouraged many groups to use virus inactivated 
vaccine strategy to generate DENV vaccine. 
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Whole virus inactivated Vaccine candidates: Inactivated virus is a nonviable 
viral particle that can not replicate in the host cells. The preparation of an inactivated 
vaccine includes the propagation of the virus in cells such as Vero cells, concentration of 
the virus particles by ultracentrifugation, purification on sucrose gradient, and 
inactivation of the virus by chemical treatment such as formalin. The virus-inactivated 
vaccine has two advantages over the live attenuated vaccines; it is safe, as it is not 
possible for the virus to retrieve its viability and cause reactogenicty in vaccinees. It 
induces a balanced antibody response and does not result in infection interference. 
Nonetheless, the virus-inactivated vaccine has its own challenges. The vaccine cannot be 
replicated in the host cells, which means that a high titer of the vaccine should be 
generated in tissue culture, which can be expensive to manufacture as DENV does not 
grow to high titer in tissue culture. Moreover, the vaccine contains only the DENV 
structure protein and fails to induce immune response to the non-structural proteins. 
Adjuvants and multiple booster of doses are required to provide long term immunity. 
These challenges make the DENV inactivated vaccine not attractive for manufacture in 
endemic area, but they may be used as military vaccines. Walter Reed Army Institute of 
Research (WRAIR) used a high titer (about 10(9) pfu per ml) purified Dengue 2 virus to 
be inactivated with formalin. The inactivated DENV-2 vaccine was used with adjuvant 
such as AS05 and AS08 to immunized macaques, which induce high neutralizing 
antibody levels after multiple doses (1).  
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Recombinant subunit vaccines candidates: DENV antigens, primarily E 
protein, have been expressed in several systems to generate protein subunit vaccine 
candidates. Escherichia coli bacteria, Pichia pastoris yeast, insect cells and mammalian 
cells have been used to generate recombinant Dengue protein such as PrM-E and C 
proteins (1). Subunit vaccine has the same advantage and disadvantage of the inactivated 
vaccine, however one principle should be considered when this strategy is used to 
generate subunit vaccine based on E protein. The E protein contains the major antigenic 
epitopes of DENVand the primary used antigen in the production of subunit vaccine; 
thus, E protein should be folded correctly to induce the right immune response. Full-
length E protein without co-expression of PrM protein will not be folded correctly, will 
be targeted intracellular, not secreted and fail to induce immune response (1). Hawaii 
Biotech generated a recombinant subunit DENV2 E protein comprised of the N-terminal 
of 80% of E and PrM (r80E) (the E protein doesn’t encode 83 a.a at its C-terminal)  
expressed in Drosophilae cells. The preclinical trial includes the immunization of rhesus 
macaques at day zero and 30 with two doses of r80E with each of five different adjuvant 
combinations. Control groups included animals immunized with saline, purified 
inactivated DENV-2 given with adjuvant or a single dose of live attenuated DENV2 
vaccine. This induced the same level of neutralizing antibodies as in the group that 
received the highest dose of antigen together with two adjuvants (1).  
DNA vaccines candidates: Comprising DENV genes into an expression plasmid 
may result in DENV DNA vaccine, which affords advantages over conventional vaccines 
including: stability for long periods of time, and resistance to extremes of temperature. 
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This mean it can be transport at room temperature and decrease the likelihood of 
reactogenicity and replication interference. Because the proteins produced by DNA 
vaccine are translated and processed within the host cell, they are able to induce class I 
MHC-dependent immune response. Nevertheless, DNA vaccine has disadvantages 
including: the necessity for multiple doses, using adjuvants and specialized injection 
equipment. Naval Medical Research Center (NMRC) introduced the DENV-2 PrM gene 
and 92% of the E gene (the E protein doesn’t include 54 a.a at its C-terminal) into the 
plasmid expression vector VR1 012. Preclinical studies in mice and monkeys carried by 
immunizing animal by two doses of the DENV-1 DNA vaccine combined with adjuvant 
were followed by challenging the animals with wild type DENV-2. The vaccine protected 
80% of the animals where the neutralizing antibody was induced in all vaccinated 
animals (126).  
Live-virus Vectored Vaccines candidates: Recombinant viruses expressing 
foreign proteins can induce strong humoral and cellular responses against infection in 
humans. The recombinant virus infects cells and expresses its proteins along with the 
foreign proteins within the cells. Those proteins are then naturally processed, 
glycosylated and associated with the cell membrane. The intracellular translation and 
processing of the proteins can induce class I MHC- dependent immune responses. 
However, the live-virus vectored vaccine will induce a restricted immune response 
depending on the foreign vectored antigen. The National Institute of Allergy and 
Infectious Diseases (NIAID) used the highly attenuated Modified Vaccinia Ankara 
(MVA) virus to express DENV-2or DEN-4 PrM and 80% of E protein. Preclinical studies 
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in mice show that the MVA-DEN2 80% E, but not the MVA-DEN4 80% E, induce 
neutralizing antibody responses in mice. Monkeys immunized twice with the MVA-
DEN2 80% E develop resistance to wild type DENV-2 challenging (127).  Naval Medical 
Research Center (NMRC) generates two bivalent DENV vaccines using complex 
adenovirus (CAdV) by introducing the PrM and E genes of DENV-1 and DENV-2 
(CAdVaxD1-2) or DENV-3 and DENV-4(CAdVaxD3-4). Preclinical studies include 
immunization of rhesus monkeys by tetravalent dengue vaccine formulated by combining 
the two bivalent vaccines   (CAdVaxD1-2) and (CAdVaxD3-4). The vaccine induced 
neutralizing antibody at high levels and protected the challenged animal with wild type 
DENV, which was administrated at 4 and 24 weeks post-immunization. CAdVaxD3-4 
completely blocked viremia while CAdVaxD1-2 significally reduced viremia in 
challenged animals (128). All these current studies building toward realizing efficient 
vaccination were faced with many challenges; however, the major challenges are 
generating tetravalent dengue vaccine that should induce protective response and prevent 
any theoretical risk of developing more serious diseases such as DSS and DHF, in 
addition to being safe, stable and coast effective vaccine. In this study we will present a 
vaccine candidate that has the ability to overcome these challenges using the live virus 
vector strategy. 
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Figure 11. Representation of various Dengue vaccine candidates antigen make up. A. 
Shows a schematic of the dengue virus genome. B. Acambis and Sanofi Pasteur vaccine 
contains for chimeric live flavivirus. The ChimeriVax tetravalent vaccine derived from the 
yellow fever virus genome with the precursor membrane (Pr-M) and envelop (E) protein 
gene segments replaced by the gene segments of each of the four serotypes of Dengue 
virus. C. The National Institute of Allergy and Infectious Diseases (NIAID) and the US 
National Institute of Health (NIH) vaccine contains a mixture of four recombinant dengue 
virus genome; DENV-1 and DENV-4 have an attenuation mutation on their 3’ 
untranslated region (UTR) known as ∆30 that are not shown in the figure. The DENV-2 
and DENV-3 component are chimeric dengue viruses derived from DENV-4 mutated 
genome with PrM and E genes replaced by serotype 2 and 3 of Dengue virus. Chimeric 
DENV-4-3 is not shown in the figure D. The Center for Disease Control and protection 
(CDC) vaccine contains a mixture of four recombinant DENV-2 genomes; the DENV-1, 
DENV-3 and DENV-4 components are chimeric dengue virus genome. The Hawaii 
Biotech vaccine is a recombinant protein vaccine containing the E glycoprotein of the four 
serotypes of Dengue virus. Other vaccines using DNA plasmid or virus vectors to express 
Dengue virus antigen inside the cell. Nature Reviews Immunology(3) 
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1.7 Hypothesis and research specific aims: We hypothesize that Measles virus (MV) 
backbone can be used as a vaccine vector to generate protective responses against both 
measles and DENV. We planned to introduce DENVantigens coding sequences 
downstream of N gene in our viral vector MVvac2. The virus vector will replicate 
effectively in tissue culture and the expression profile of Dengue antigens will be high. 
Since recombination or deletion has not been demonstrated in MV, we propose this 
vaccine will be stable enough to be tested in experimental animals for immunogenicity 
studies. 
1.7.1 Research specific aims:                                                                                                                            
I. Generating MVvectoring DENV2-4 glycoproteins: 
 A. Amplification of two forms of DENV PrME; Full length form which will 
include the coding sequence of the PrM-E glycoproteins (DENV2 strain 16681, PrM 
amino acid sequence (166 a. a.) ,and E is 495 a.a based on reference Hahn et la. DENV4 
strain ATCC VR 217 PrM  (166 a.a) and E is 493 a.a based on reference Zhao et al.) 
which will be translated and processed intracellularly. This protein expression plan has 
the potential to induce the formation of virus like particles. Soluble form which will 
include the PrM-E proteins without the transmembrane domain of E protein (does not 
include 45 a.a at the protein C-terminal, DENV2 sE does not include a.a # 730 to 775, 
DENV4 doesn’t include a.a # 728 to 773). The protein will be secreted to extracellular 
space by the cellular secretory system. 
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B. Cloning Dengue antigens into MVvector; each of the two forms of either 
DENV2 or DENV4 will be inserted downstream of N gene in the MVvector MVvac2 
(see figure 7).  
II. Recovery of recombinant MVvector:  
A. Using reverse genetic technology, MVvectoring Dengue antigens will be 
rescued from a full-length infectious cDNA plasmid in vitro.  
B. Replication fitness of recombinant MVwill be characterized by multi-step 
growth kinetics in Vero/h SLAM cells.                                                                                                   
III. Characterization of measles and Dengue glycoprotein expression 
  A. Corroboration of insertion of Dengue glycoprotein coding sequences using RT-
PCR.  The insertion of Dengue genes will be detected from total RNA obtained from 
infected cells. 
B.  By western blot, a monoclonal antibody directed against Dengue glycoprotein 
E will be used to corroborate expression of the vectored antigens. Anti Measles 
glycoprotein H or N will be used as controls. 
C. Indirect Immunofluorescence assay, polyclonal sera directed against Measles 
glycoprotein N (positive control) and monoclonal antibodies against Dengue 
glycoproteins PrM and E will be used to corroborate the expression of antigens.   
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Figure12. Representation of Measles Virus structure, RNA genome and proteins. a, 
Measles virion structure and organization. Measles virus is negative single stranded RNA 
virus contains a lipid envelop with two viral glycoproteins, MV-H and MV-F bind to Matrix 
(M) protein though cytoplasmic tail. The genomic RNA is covered by nucliocapsid (N) 
protein and bind to phosphoprotein (P) and Large (L) protein to form RNP complex. b, the 
organization of measles RNA genome. It encodes 6 genes. Structural genes includes F,H and 
M and non-structural genes includes L and p which includes two overlapping open reading 
frames C and V.  The 3’ end of the genomic RNA has the leader sequence where the RdRp 
will bind to initiate the transcription. RdRp generates a transcription gradient of measles 
mRNAs. N protein has the higher expression level. 
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1.8 Measles virus Vector: Measles virus (MV) is a negative sense – single stranded 
RNA virus of the Paramyxoviridae family. The MV proteins Include, Nucleocapsid (N) 
protein, Phosphoprotein (P), Hemagglutinin (H), Fusion (F) protein, Matrix (M) protein 
and an RNA-dependent RNA polymerase (L) protein (figure 12 a, b) (5). Measles is an 
enveloped pleomorphic virus, it has two glycoproteins H and F arranged on the surface of 
the virion. H is a type II integral membrane protein that is responsible for attachment of 
the virus to a cell receptor present on the cell surface. The MV has 3 known receptors, 
which determine the tropism of MV within the host cells. CD 46 (membrane cofactor 
protein) present on the surface of almost all nucleated human cells(129). CD 150 or 
SLAM (Signaling lymphocyte Activation Molecule) marker on the surface of activated 
lymphocytes. (130) Nectin-4 is a tight junction protein that mediate the MVentry into 
epithelial cells (131). The other glycoprotein is the F protein. It is a type I integral 
membrane protein which present in an immature form called F0 and will be cleaved by 
cellular proteases prior to virus releasing from the cells in order to expose its hydrophobic 
fusion peptide. Mature virus has two subunit of F protein F1 and F2 that is responsible 
for the fusion and the entry of the virus into the host cells. When the virus binds to the 
cell surface receptor, F1/F2 protein will go through conformational changes at neutral pH 
where the fusion peptide will be inserted into the plasma membrane. The virus membrane 
will be fused into the cell membrane and the virus genetic material will be released. Both 
H and F proteins are integrated to the virus membrane through cytoplasmic tail, which 
are bound to the Matrix (M) protein. M protein lines the inner surfaces of the virus 
envelop. It plays a role in the virus assembly and provides a support for the glycoprotein. 
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After the virus entry the genome will be released into the cytoplasm of the infected cells. 
MV genome is covered by the Nucleocapsid (N) protein and associates with L protein 
and P (5). The N protein is the most abundant protein among measles proteins and it 
plays a critical role in the viral replication, as it will be discussed. L protein is responsible 
for the transcription and replication of the RNA genome. In addition to the L protein the 
virus carry the P protein since it is an essential polymerase cofactor. The MV P gene 
codes for not only the P protein but also for other two proteins:  V and C, which are not 
strictly required for viral propagation in cultured cells but required for the viral 
replication in the host cells (see figure 13). The V and C protein play a role in the control 
of the innate immune response, antagonizing the interferon pathway. 
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Figure 13. Representation of Measles virus replication in the cytoplasm of infected cell. 
Negative stranded RNA genome covered by N protein and bind to P and L proteins will be 
released into the cytoplasm of infected cells after virus entry. The L protein or the RdRp will 
de attach from the RNP complex and will bind to the leader sequence at 3’ end to start the 
replication process. The genomic RNA will transcribe into negative strand or antigenomic 
RNA which is used as a template for replication and production of more negative stranded 
RNA genome. The genomic RNA will be transcribed into viral mRNAs that will be translated 
by cellular mechanism into proteins.  Measles F and H protein will be directed to the ER to be 
glycosylated and secreted to the plasma membrane. The M protein will be bind to the 
cytoplasmic face of the plasma membrane. The replicated genomic RNA will bind to the N, P 
and L proteins to form RNP complex, which will be transported to the plasma membrane. 
Once the RNP bind to the M protein a complex will be formed and the virus will bud from the 
cell surface. Current Opinion in Microbiology(5)  
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The Measles RNA genome is used as a template to be transcribed to generate a 
full-length messenger RNA. Thus, the replication of Measles genome happens in two 
steps. The first one consist of when the RdRp will bind to the leader sequence at 3’ end of 
the genome to generate a positive stranded, full-length RNA called anti-genomic RNA. 
The second one happens when the RdRp use the anti-genomic RNA as a template to 
generate multiple copies of the genomic RNA (Figure 13) (5). In comparison, 
transcription happens in a multi-step process where the RdRp will bind to the leader 
sequence to transcribe each of MV cistrons in a gradient manner. Transcripts close to the 
genomic 3’ end are more abundant, N protein has the higher expression level while L 
protein has the lowest (Figure 14). 
 
  
Figure 14. Represent the relative transcript levels of the six measles genes. The measles 
polymerase generates transcription gradients of the measles genes. The genes downstream the 
3’ end will have lower level of expression. N protein has the highest level while L protein has 
the lowest level of expression. The measles genome has an intragenic region between each 
gene. The polymerase will attenuate for a second after transcribing the gene and then it will 
released from the genome to bind again to the leader sequence at the 3’ end of the genome and 
start the transcription all over again. As a result the polymerase will generate different amount 
of the viral mRNA. Current Topics in Microbiology and Immunology  
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  The MV has two distinctive features, Measles genome is only biologically active 
when it is present as RNP complex, which means that the virus should be encapsidated 
into the N protein in order to be transcribed and replicated. As a member of 
Paramyxovirus, measles has another distinctive feature called rule of six. Measles has a 
restriction for the genome replication. The length of the genomic RNA or the anti-
genomic RNA should be a multiple of six nucleotides in order to be encapsidated into the 
N protein.  As the RdRp elongates the genomic or the anti-genomic RNA the N protein 
monomers will bind to units of six-nucleotides (hexamers). Due to those two features the 
RNA genomes that are not hexameric will not be packaged into the RNP complex and 
will replication capabilities. The viral mRNAs will be translated in the cytoplasm.  N, P 
and L proteins will be used in the viral replication while the M protein will be directed to 
the plasma membrane. The H and F protein will be directed to the endoplasmic reticulum 
to be synthesized and transported via the Golgi apparatus to the plasma membrane. As 
the proteins are transported to the plasma membrane H and F protein will be glycosylated 
and cleaved to generate mature forms. The glycoprotein complex will be assembled on 
the cell surface and will bind to the M protein that binds to the cytoplasmic face of the 
plasma membrane (figure 13) (5). Encapsidated genome will bind to the M protein and 
afterwards the virus will bud from the cell surface. Generally, most of the new 
synthesized virus particles are not released into the extracellular space. The newly 
accumulated H and F glycoprotein at the surface of the infected cell membrane can result 
in fusion between neighboring cells. Syncytia formation is one of the known signs of 
measles infection in the culture cells. Syncytia formed due to the fusion of infected cells 
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results in passing infectious virions between cells without releasing virus particles (5).  In 
this research, the MV vector” MVvac2” that was generated from Schwarz vaccine strain 
is used as backbone to generate Dengue divalent candidates.  From a vial of Schwarz 
vaccine, Measles antigenomic RNAs were isolated which used to generate full-length 
cDNA of measles genome using RT-PCR. The cDNA was used to generate pB (+) 
MVvac plasmid. Three mutation within the polymerase gene of pB(+)MVvac was 
corrected  (132). The corrected plasmid was named pB(+)MVvac2.  To facilitate cloning 
of foreign coding sequences into pB(+)MVvac2 vector, additional transcription units  
(ATUs) were introduced into the vector in many positions. In this research, 
pB(+)MVvac2 with an ATU located in position 1710 downstream the N gene (see figure 
16) is used as a virus vector to express DENVantigen. The foreign antigen sequence can 
be introduced in intragenic regions, which direct the transcription by RdRp. The genomic 
location of the ATU determines how much protein will be expressed. ATUs have been 
inserted into different locations including downstream P, downstream H and downstream 
L and upstream N genes. Attenuated MV vaccine is one of the most stable, safe and 
effective human vaccines. Vaccination using measles vaccine is protective for life against 
MV infection. This strong and durable protection should be applied in case of MV 
expressing antigen of other pathogens. MV vaccine vector has many advantages in the 
means of expressing foreign antigen. In comparing top DNA viruses, recombinant MV 
vaccine is safe because it replicates in the cytoplasm of the cells. Thus, the danger of 
integration into the human genome is excluded.                                                                                                                                                                          
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Figure 15. Rescue methods of the Measles virus and recombinant measles virus using 
standard cell line.  Simultaneous transfection of cells that support measles replication like 
293 cells. Each of the three plasmid carry N, P protein or T7 polymerase. Plasmids have a 
cytomegalovirus (CMV) promoter which bind to the cellular RNA polymerase to express the 
N , P proteins and T7 polymerase.  pEMc-La has the L protein coding sequence primed by 
internal ribosome entry site (IRES) to ensure the translation of the L gene into the RdRp. 
P(+)MV will transcribed by T7 polymerase into full length antigenomic RNA which serve as 
template for the replication and the production of the genomic RNA. The N and P and L 
protein will bind to the genomic RNA to form RNP complex. MV genome as RNP will 
generate and express the viral mRNAs into viral protein by cellular machinery. The measles 
virus will assemble and released from the cell. Current Topics in Microbiology and 
Immunology (2)   
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In addition, the small size of MV in comparison to DNA virus gives MV advantage of 
replicating more robustly. In comparing to other RNA viruses measles has high genetic 
stability. Also, MV can carry high load of insert with no restriction by its helical capsid 
structure in compare to other RNA viruses.  
In summary, the MV vaccine is safe and it has been used in for more than five 
decades, with a well-established production and distribution networks, replicate in the 
cytoplasm and easy to use in reverse genetic technology . So, using the MV vaccine as a 
backbone to generate the Dengue vaccine will make the preclinical tests easier. The 
industry of the MV vaccine is a well-established industry. Thus, we can get production 
lines for dengue vaccine based on the MV vector much easier. This will make the cost of 
the vaccine production cheaper than other vaccine candidates. 
 A reverse genetic system has been established to allow the rescue of MV from 
cloned DNA. The first attempt to rescue MV was done by using helper virus.  In this 
method, the cells will be infected with vaccinia virus expressing T7 RNA polymerase at 
high level. The cells then will be transfected by cDNA of measles genome along with 
plasmid encoding N,P and L genes under the control of a T7 promoter which will be 
recognized by the T7 RNA polymerase to initiate the transcription of those genes. The N, 
P and L protein will be used in the replication of the transcribed genome (2). 
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The helper virus approach is an effective way to rescue viruses but it is not the 
most effective strategy to rescue MV since a cumbersome purification step was 
necessary. Thus, the rescued virus progenies should be purified by filtration. MV is easily 
inactivated by chemical and physical stress during the filtration process (2). Thus, another 
system not including the helper virus should be used in case of MV rescue. Simultaneous 
plasmids transfection is more efficient that the helper virus system.  A cell line will be 
transfected by a group of plasmids. Three plasmids carry T7 polymerase gene, N gene 
and P gene.  The plasmids have a strong promoter, which will be recognized by the 
cellular RNA polymerase III such as CMV (Cytomegalovirus) promoter.  N and P protein 
will be used to initiate the measles genome replication .T7 polymerase will start to 
transcribe the other plasmids which carry the L protein and a full-length cDNA of 
	
Figure 16. Represent the Map of pB(+)MVvac2(ATU)N plasmid. The upper part 
represent the plasmid containing an MV genome with vaccine-identical coding 
sequence. The genes of MV are represented by arrow dark gray boxes. The T7 
promoter and T7 terminator are indicated. They flanked the measles genome to 
regulate the transcription by the T7 polymerase. HδR. hepatitis delta virus ribozyme. 
The additional transcription unit (ATU) cassette was added in 1710 position within the 
measles vector, which located at the downstream of N gene in measles genome. The 
bottom part represents the nucleotide sequence of the ATU. The conserved 
termination, intragenic, and initiation nucleotides are underlined. The restriction site 
of the multi cloning site are indicated, which are MluI, BsiWI, NurI, SnaBI, BssHII 
and AatII.   
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measles genome (figure 17). Any cell line that supports the MV replication could be used 
in this method. Helper cells (293-3-46) express P protein, N protein and T7 polymerase it 
was first used by Redacke to rescue MV( See figure 18) (2). It will be explained in the 
material and methods section.  The progeny of rescue MV will be propagated by 
overlaying the rescue cells by cell line that supports measles entry and replication such as 
Vero cells expresses SLAM.  
The ability of MV to incorporate ATU into their genome and with the presence of 
established rescue system. Measles could be used to insert foreign coding sequence such 
as marker genes to localize the replication of MVwithin the host cells and organs and 
genes from other pathogen to generate multivalent vaccines. MV vector was first used to 
generate multivalent vaccine against Hepatitis B virus (HBV). HB surface Ag (HBsAg) 
coding sequence was introduced into multiple locations on measles genome. The 
recombinant measles successfully expressed the HBsAg.  Furthermore, vectored vaccines 
remain protective against a MV challenge in a natural susceptible model (non-human 
primates) Thus, the hope that recombinant measles expressing an antigen of other 
pathogens has a documented substrate in order to generate multivalent vaccines.  
With the high demand to generate effective vaccine for virus members of Flavivirdia 
such as yellow fever (YF), Japanese encephalitis, Dengue fever and West Nile fever 
(WN) Previous reports have documented the use of MV in developing multivalent 
vaccine for at least three Flavivirus. 
a) MV expressing a secreted form of E glycoprotein (Es) from West Nile virus showed 
that protective responses against measles and WNV could be obtained 
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simultaneously (133). The coding sequence of the WNV Es was inserted downstream 
of P gene in measles genome. WNV protective immune responses were documented 
in CD46-IFNarko mice from WNV infection. Those mice are not responsive to INF-
α/β and express on of MV receptors. The controlled animal died within 3-4 days after 
WNV infection challenge while the immunized group shows no mortality. As 
conclusion, the multivalent vaccine protect highly susceptible animal from WNV 
infection (133)   
b) In an effort to generate a vaccine, Tangy group introduced the DIII of E glycoprotein 
coding sequence fused to the ectodomain of M protein coding sequance into 
downstream of P gene in measles genome (134).   
c) Hepatitis C virus. HCV infection causes a serious health problem worldwide with no 
treatment and no vaccine. Roberto Cattaneo group used MV vaccine to express the 
two HCV glycoproteins. The coding sequence of E1 and E2 glycoprotein of HCV 
were inserted into downstream of P gene. Neutralizing immune responses against 
HCV were generated in immunized mice (135). 
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Chapter 2. MATERIAL AND METHODS 
2.1 Cells and Viruses. Vero/hSLAM cells ( African green monkey kidney cells 
expressing SLAM receptor on the cell surface) and the helper 293-3-46 cell line were 
maintained as monolayers in Dulbecco’s modified Eagle’s medium (DMEM) supplement 
with 5/10% fetal calf serum, and 0.5 (Vero/hSLAM) or  1.2 (293-3-46) mg/ml G 418. 
BHK21 cells were grown in minimal essential medium (MEM, Gibco-BRL) 
supplemented with 10% fetal calf serum (GIBCO-BRL), 2 g/l sodium bicarbonate, 50 
U/ml of penicillin and 50 μg/ml of streptomycin. Life attenuated Schwarz MV vaccine 
strain, to prepare virus stocks Vero/hSLAM cells were infected at multiplicity of 
infection (MOI) of 0.03 and incubated at 37 °C When cytopatic effect (CPE) of 80% 
were reached they were collected in Opti-MEM and infectious particles released by two 
freeze-thaw cycles. The virus aliquot were titrated and storage at -80 °C. DENV 2 
(16681) and DENV 4(ATCC VR 217)  to prepare virus stock Vero/hSLAM cells were 
infected by MOI of 1 and incubated at 37 °C for 5 days. Virus aliquot made by collecting 
the supernatant from infected cell line. The virus aliquots were titrated and storage at –80 
°C.                                                 
2.2 Plasmids and Plasmids construction. The plasmid pB(+)MVvac2(HBsAg)N 
contains an infectious MV cDNA  corresponding the antigenome of the Schwarz measles 
vaccine strain and has the sequence of Hepatitis B surface antigen (HBsAg) coding 
sequence inserted downstream N gene (See Figure 19)  pB (+)MVvac2(HBsAg)N was 
used to introduce DENV 2 and 4 coding sequences (PrME and PrMEsol) into 
downstream N. pJet plasmid containing the corresponding DENV 2 and 4 coding 
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sequences was used as an intermediate vector. DENV 2 coding sequences were obtained 
from PD2/I/C/30P/A plasmid containing cDNA of DENV 2 and is used to isolate the full 
length PrME coding sequence and the soluble PrMEsol coding sequence.  pR424-D4 
plasmid contains cDNA of DENV 4 and is used to isolate the full length PrME coding 
sequence and the soluble PrMEsol coding sequence. PD2/I/C/30P/A plasmid and PR424 
plasmid were used as templates to amplify DENV 2 PrME/PrMEsol and DEN4 
PrME/PrMEsol, respectively by PCR,. RA-prME DEN2 Fwd forward primer was used in 
the reaction of amplifying DEN2 PrME and PrME sol ( see table2).  RA-prME DEN2 
REV2 reverse primer and   RA-prME DEN2 sol REV2 reverse primer were used to 
amplify the DEN2 PrME and PrMEsol, respectively (see table2).  
Table 2.  
Primers to amplify dengue antigen coding sequence. 
Name  Sequence  Hybridization  
RA-prME DEN2 
Fwd 
5’TCAGCACGCGTATGTCTGCAGGCATGATCATT3’ DEN2 cDNA C 
gene 
RA-prME DEN2 
REV2 
5’ACGATGCGCGCTTAATCGGCCTGCACCATG3’ DEN2 cDNA E 
gene 
RA-prME DEN2 
sol REV2 
5’ATCAGGCGCGCTTATTAAACCCCACTGAAGGCAG3’ DEN2 cDNA E 
gene 
RA-prME DEN4 
fwd 
5’ACTGTACGCGTATGTCAACGATAACATTGCTGT3’ DEN4 cDNA C 
gene 
RA-prME DEN4 
rev                      
5’ACGGTGCGCGCCTACTATGCTTGAACTGTGAAGCC3’  DEN4 cDNA E 
gene 
RA-prME DEN4 
sol REV2      
5’ACGGTGCGCGCCTACTAGACTCCTCCAAACATGGT3’     DEN4 cDNA E 
gene  
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RA-PrME DEN4 fwd forward primer was used in the reaction of amplifying DENV4 
PrME and PrME sol (see table2). RA-prME DEN4 rev reverse primer and   RA-prME 
DEN4 sol REV2 reverse primer were used to amplify the DENV2 PrME and PrMEsol, 
respectively (see table2). The Forward primers were design to add Mlu I recognition site 
and start codon sequence into the 5’ end of the inserts, Also the reverse primers were 
design to add stop codon and BssH II recognition site sequence into the 3’ end of the 
inserts (see table 2 and figure19). PCR reaction was performed as follows 2ug of the 
templates and 0.2ul of phusion DNA polymerase were used in a 50 mL PCR reaction 
with annealing temperature of 52 °C The amplified Genes were introduce into pJet 
plasmid using pJET PCR Cloning Kit (Thermo Scientific) to generate 
pJETDEN2(PrME), pJETDEN2(PrMEsol), pJETDEN4(PrME)and 
pJETDEN4(PrMEsol). The cloned plasmids were transformed into XL-1 blue competent 
cells and grow over night at 37 °C. Colonies were selected and analyzed to be used in a 
Mini-prep using QIAGEN Plasmid Mini Kit ( QIAGEN). The cloned pJet plasmids were 
sequenced using pJET1.2 Fwd, 23-mer forward primer and PJET1.2 Rev, 24-mer reverse 
primer which are included in the pJET PCR cloning kit (see Table 3). The Cloned pJET 
plasmids and the pB(+)MVvac2(HBsAg)N plasmid were digested by MluI and BssH II 
restriction endonucleases enzymes. The digestion reactions were incubated at 37 °C for 1 
hr. and 25 ul of the reactions were used to run on 0.8% agarose gel to isolated the 
*Red italic is Mlu I restriction enzyme recognition sequence *Blue italic is BssH II 
restriction enzyme recognition sequence **Bold is start/stop coding 
sequence***Underlined additional nucleotides to comply with the rule of six. 
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digested inserts, DEN2 PrME/PrMEsol and DEN4 PrME/PrMEsol and the 
pB(+)MVvac2(ATU)N plasmid using QIAquick Gel Extraction Kit  (Qiagen). T 4 ligase 
is used to ligate the DEN2 PrME/PrMEsol and DEN4 PrME/PrMEsol into the 
pB(+)MVvac2(ATU)N, ligation reaction incubated at 14 °C overnight and 5 ul of ligation 
reaction are transformed into XL-1 blue competent cells. Plasmid extracted from bacterial 
culture by using QIAGEN plasmid Maxi Prep KIT (Qiagen) Four plasmid constract were 
generated  pB(+)MVvac2DEN2(PrME)N, pB(+)MVvac2DEN2(PrMEsol), 
pB(+)MVvac2DEN4(PrME)N and pB(+)MVvac2DEN4(PrMEsol) (see figure19) . The 
plasmids construct were analyzed by restriction enzymes digestion and by sequencing 
using 1681-FWD, DEN 2 E Fwd1 and DEN2 Fwd2 primers to sequence 
pB(+)MVvac2DEN2(PrME)N and  pB(+)MVvac2DEN2(PrMEsol). 1681-FWD, DEN4 
E Fwd1 and DEN4 E Fwd2 primers to sequence  pB(+)MVvac2DEN4(PrME)N  and 
pB(+)MVvac2DEN4(PrMEsol) (see Table 3). 
Table 3 
Sequencing primers  
Name Sequence  Hybridization  
1681-FWD 5’ACTAGGTGCGAGAGG3’ MVvac2 nucleotide 
#1681  
DEN 2 E Fwd1 5’AAGGAAGTACTGTATAGA3’ DEN2 cDNA E gene 
DEN2 Fwd2 5’CAGAGTGCAATATGAAGG3’ DEN2 cDNA E gene 
DEN4 E Fwd1 5’AGTGGCTCTGTTAAGAAC3’ DEN4 cDNA E gene 
DEN4 E Fwd2 5’ACAACAGTGGTGAAAGTC3’ DEN4 cDNA E gene 
pJET1.2 Fwd, 23 5’CGACTCACTATAGGGAGAGCGC3’ PJET1.2/blunt vector  
PJET1.2 Rev, 24 5’AAGAACATCGATTTTCCATGGCAG3’ PJET1.2/blunt vector 
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Mutagenesis. Correction of mutation present in DEN4 E protein domain III by 
two step PCR extension and overlapping PCR (see figure18). The DEN4 PrME was used 
as template and DNA polymerase and mutagenesis primer (see table 4) in a site specific 
nucleotide substitution extension PCR to correct the wrong nucleotide. Two products 
were isolated and cleaned up using a DNA Colum. The products were used in an 
overlapping PCR reaction using phusion DNA polymerase and 52 °C annealing 
temperature.  
Table 4  
Mutagenesis primers 
Name  Sequence  Hybridization 
DEN4-  mut.FWD1 5’ACTGTACGCGTATGTCAACGATAA3’ DEN4 E gene 
DEN4- mut.FWD2 5’ATGTCATACACGATGTGTTCA3’ DEN4 E gene 
DEN4- mut.REV1 5’ACGGTGACGTCTACTATGCTTGAACTG3’ DEN4 E gene 
DEN4- mut.REV2 5’GAACACATCGTGTATGACAT3’ DEN4 E gene 
  
2.3 Virus Rescue and syncytium Formation. A transfection mix was prepared by 1 ug 
of pEMC-La (plasmid encoding MV L protein) mixed with 10 ug of each plasmid 
construct pB(+)MVvac2DEN2(PrME)N, pB(+)MVvac2DEN2(PrMEsol)N, 
pB(+)MVvac2DEN4(PrME)N , pB(+)MVvac2DEN4(PrMEsol) and 
pB(+)MVvac2(GFP)N  which encodes green fluorescent protein and was used as positive 
control. The plasmids were mixed with CaCl2 and 2X Hepes-Buffered-Saline (2X HBS) 
provided by Calcium phosphate precipitation promega kit (Promega). The mixes were 
incubated at room temperature for 30 min and then used to transfect helper 293-3-46 cells 
stably expressing MV-N, MV-P, and T7 polymerase (see figure18).  
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Figure 17. Schematic representation of mutagenesis PCR. Stage A include substitution of 
the wrong nucleotide with the correct one using mutagenesis primers. DEN4-mut.FWD1 and 
DEN4-mut.REV1 (Bark blue arrows) were used in PCR reaction 1 and generated Product-1. 
DEN-4mut.FWD2 and DEN4-mut. REV2 (Red arrows) were used in PCR reaction 2 and 
generated product-2. Stage B include overlapping PCR to generate the DEN4 E protein 
sequence with the corrected nucleotide. In this stage product-1 and product-2 are combined 
without primers. The overlapping PCR includes denaturing of product-1 and 2, re-annealing to 
form heteroduplexs of both products and extension using DNA polymerase to generate the 
final product.   
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Figure 18. Representation of the measles virus rescue strategy. Measles virus plasmid 
vector MV contain T7 promoter and TǾ RNA polymerase terminator flanking the measles 
genes. L-encoding plasmid PEMC-La contain internal ribosome entry site (IRES) to 
ensure the translation of L gene into RNA polymerase. Both plasmids will transfect helper 
cells (293-3-46) which express the nucleoprotein N, phosphoprotein P and T7 polymerase. 
In the cytoplasm of the helper cells T7 RNA polymerases will transcript positive, single 
stranded RNA from the measles cDNA plasmid. The positive single stranded RNA will be 
encapsidated by THE N and P protein, which are expressed by the helper cells. The RNA 
polymerases will transcript a negative single stranded RNA, which represents the measles 
genome. The measles virus proteins will be translated from the measles RNA genome.  
These proteins will be used for virus assembly. The measles virus particles will released 
from the cell to infect other cells (2).  
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The helper 293-3-46 cells were seeded early into six well plates and incubated at 
37 °C for 5-6 hr. to rich 50-60 % confluence. Transfected helper 293-3-46 cells were 
incubated at 37 °C over night. After incubation time the cells were heat shocked for 3 
hours at 42 °C to induce the translation of L proteins (The RNA polymerase). The heat 
shocked helper cells were incubated at 37 °C over night to recover. In the next day, each 
well of the six well plates were overlaid into Vero/hSLAM cells which were seeded into 
100mm plates(p 100) earlier and incubated at 37 °C to rich 50% confluent.  The p 100 
plate of each virus was incubated at 37 °C and was examined for syncytium formation. 
MVvac2 (GFP N plate was examined by inverted microscope with epifluorescence 
illumination (EVOS FL.) using the GFP channel to examine the syncytium with green 
fluoresce. The other virus constructs; MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol), 
MVvac2DEN4(PrME)N and MVvac2DEN4(PrMEsol)  were examined for syncytium 
formation by inverted microscope (ZEISS) using 4 X and 10 X magnification objective 
lenses. Green syncytium were detected one day later after incubation of overlaid cells at 
37 °C (see figure). Picking up single syncytium to grow isolated clones depended on the 
level of infection ; Single clone syncytia was collected 4 days after incubation of overlaid 
cells in p 100 plates of MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol), 
MVvac2DEN4(PrME)N and MVvac2DEN4(PrMEsol). Single clone syncytia was 
collected by scrubbing it with 1 ul of Opti-MEM. Each one of the collected syncytium 
were than used to infect one well seeded with Vero/hSLAM cells in six well plates. The 
six well plates were incubated at 37 °C and were examined for cytopatic effect. Two days 
after the incubation, single clones were collected from the six well plates of 
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MVvac2DEN2(PrME)N and MVvac2DEN4(PrME)N.  Three and four days after the 
incubation, single clones were collected from the six well plates of 
MVvac2DEN2(PrMEsol)N and MVvac2DEN4(PrMEsol)N, respectively. The single 
clones were collected by scrubbing the cells from each well by 2 ul Opti-MEM and 
transfer it into vial labeled as Virus passage zero and storage at –80 °C. To generate virus 
stocks of the four virus constructed, the viruses were passaged in cell culture to propagate 
the virus until it reach maximum titers.  The virus prep of passage zero was released by 
two freeze-thaw cycles.  ‘Blind’ passages were made by using 25 ul of passage zero virus 
to infect p 100 plates seeded with Vero/hSLAM cells with 50 % confluent and incubated 
at 32 °C. The pates were examined for cytopatic effect of 70-80 % , where the infected 
cells were collected and the virus particles released by two freeze-thaw cycles and saved 
as passage one at -80 °C. MVvac2DEN2(PrME)N, MVvac2DEN4(PrME) and 
MVvac2DEN2(PrMEsol) passage one were titrated. MVvac2DEN2(PrMEsol) virus was 
passaged two more times until it reached decent titer. 
2.4 Virus Titration. MV and recombinant MV were titrated by TCID50 (50 % Tissue 
Culture Infectious Dose) titration method which is based on the end-point dilution assays. 
Vero/hSLAM cells were seeded into 96 well plates (2x104 cells and 0.25 ml of DEMEM 
per well). Incubate the 96 well plates at 32 °C for one hour. A serial dilution of the virus 
suspension from 1 to 12 were used to infect 8 replicates of Vero/hSLAM cells seeded 
wells. The 96 well plates will be incubated at 32 °C with 5% CO2 supply for 3 days. The 
TCID50 was then calculated using the Spearman-Karber method (karber, G. 1931). 
DENV 2 and 4 were titrated by plaque assay on confluent monolayers of BHK-21 cells 
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grown in 24-well plates. A serial dilution of virus suspension from 1 to 8 were used to 
infect the BHK-21 cells reached 80 to 90% confluence in duplicate. The 48 well plates 
will be incubated 4 hours at 32 °C for viral adsorption, the BHK-21 cell monolayers were 
overlaid with MEM containing 3% carboximethil-cellulose (Sigma), 0.5% fetal calf 
serum and 2 mM L-glutamine. The cultures were incubated at 37°C for 7 days. After 
incubation period the cells was fixed with 10% formalin and staining 0.5% naphtol-blue-
black (Sigma) and then counted for plaque formation. The titer of the virus stock was 
calculated in plaque forming units per milliliter (PFU/ml). 
  
Figure 19, Experimental design used in this study. (A) Schematic representation of the DEN 
V polyprotein cDNA, DEN V PrME and PrMEsol insert. Signal peptide, double-spanning 
transmembrane domain, Mlu I recognition site/ start codon sequences and stop codon/ BSSH 
II recognition site sequences are indicated by solid black box, striped black box, striped blue 
box and solid blue box, respectively. Schematic representation of recombinant MV. Includes 
recombinant MV with HBsAg, DEN2PrME, DEN2PrMEsol, DEN4PrME and DEN4PrMEsol 
coding sequences inserted downstream N gene.  For details about pB(+)MVvac2 vector (see 
figure 16). The recombinant pB(+)MVvac2 plasmids carried Dengue 2 and 4 antigens were 
rescued and generated four clone D2-2, A.4, 1.6.2 and 2.4.1. 
 
74 
 
 
2.5 Virus Growth kinetics. Vero/hSLAM cells were seeded into six well plates (5 × 105 
cells and 2ml DMEM per well) were infected by MVvac2, MVvac2DEN2(PrME)N, 
MVvac2DEN2(PrMEsol)N and MVvac2DEN4(PrME)N at an MOI of 0.03 . At the 
indicated time points (12, 24, 36, 48, 72and 96 hr.) supernatants were cleared by 
centrifugation and saved as extracellular virus suspension, cells were scraped in Opti-
MEM (Gibco) as intracellular virus suspension and subjected to freeze-thaw cycles.  The 
extracellular virus suspension (released) and intracellular virus suspension (cell-
associated) titers were determined by TCID50 titration. A serial dilution of the virus 
suspension from 1 to 8 were used to infect duplicate of Vero/hSLAM cells seeded into 96 
well plates. The plates will be incubated at 32 °C with 5% CO2 supply for 3 days. 
2.6 RNA extraction and RT-PCR. RNA were extracted from virus suspension of MV, 
DENV 2 and recombinant MV using Trizol, 0.2 ml of chloroform to 1ml of Trizol 
reagent. The homogenized samples were centrifuged by 12000 X g for 15 min at 4 °C. 
the upper colorless aqueous phase was mixed with 0.5ml of 100% isopropanol per 1 ml 
of Trizol and centrifuged at 12000 X g for 10 min at 4 C to pellet the RNA. The pellet 
were air dried for 10 min and resuspended by 50 ul of water. 1 ug of the RNA extraction 
was used with Titan one tube Rt-PCR kit and system (Rache) to amplify DENV 2 PrME 
coding sequence using  RA-prME DEN2 Fwd , RA-prME DEN2 REV2  and  RA-prME 
DEN2 sol REV2 primers set ( see Table 2). 
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2.7 Western Blot Assay. Vero/hSLAM cells were seeded into p 100 plates and infected 
at multiplicity of infection of (MOI) 0.5 of MV, recombinant MV and DENV 2. 48 hours 
after incubation at 32 °C , the cells were lysed by RSB NP-40 0.5%. The protein lysates 
from Vero/hSLAM cells were fractionated by SDS-PAGE gel electrophoresis and 
transferred to cellulose membranes (Biorad). The blots were probed with a monoclonal 
antibody directed against DENV1,2,3,4 E protein at 1:1000 dillution (a mouse IgG2a cat. 
# ab9202 from abcam), against actin at 1:1000 dillution (a mouse IgG from SIGMA) and 
a polyclonal antibodies directed against MV N protein at 1:5000 dillution ( a rabbit IgG 
antibody provided from R. Cattaneo) and Measles H protein cytoplasmic tail at 1:1000 
dillution  ( a rabbit IgG antibody provided from R. Cattaneo ) [ Cathomen.T.,H.Y.Naim, 
1998]. A goat anti-mouse IgG, and a goat anti-rabbit IgG, alkaline phosphatase 
conjugated (Thermo Fisher Scientific) used as a secondary antibody at 1:1000 dilution. 
Alkaline phosphatase activity was visualized with Western Blue Stabilized substrate for 
alkaline phosphate reagent (Promega).   
2.8 Indirect Immunofluorescence Microscopy. Vero/hSLAM cells were seeded into 4 
well glass Millicell EZ slides (MILLPORE) and infected at MOI of 0.06, 0.1 and 1 with 
MV, recombinant MV DENV2 and 4, respectively. After 48 hours of incubation at 32 C, 
the cells were fixed with 3% paraformaldehyde and incubated at 32 °C overnight. The 
cells were permeabilized with 0.1% Triton X-100 in phosphate- buffer saline (PBS).  
Both primary and secondary antibodies dilution were prepared in 0.1% triton X-100 in 
10% FBS serum in 1 X PBS. Two Mixes of primary antibodies were used, monoclonal 
antibody directed against DENV 1,2,3,4 E protein at 1:50 dilution (a mouse IgG2a cat. # 
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ab9202 from abcam) with the polyclonal antibodies directed against MV N protein at 
1:300 dilution ( a rabbit IgG antibody provided from R. Cattaneo) and  monoclonal 
antibody directed against DENV 1,2,3,4 PrM protein at 1:50 dilution (a mouse IgG cat. # 
ab41473 from abcam) with the polyclonal antibodies directed against MV N protein at 
1:300 dilution ( a rabbit IgG antibody provided from R. Cattaneo    .The primary 
antibodies incubations were carried out overnight at 4 °C. A mix of goat anti-mouse IgG 
coupled to Fitc (Green fluorescence), and a goat anti-rabbit IgG coupled to PE (Red 
fluorescence) were used as a secondary antibodies with dilution of 1:300 and incubated at 
room temperature for 2 hours. The coverslips were mounted on slides by using 
flouromount G with DAPI (Electron Microscopy Science).  The slides examined and 
images were taken by inverted microscope with epifluorescence illumination (EVOS 
FL.).  
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Chapter 3. RESULT 
 
3.1 Generation of four MVvac2 full-length plasmids vectoring Dengue 2 and 4 
glycoprotein coding sequences. After amplification by PCR, the DEN2PrME, 
DEN2PrMEsol, DEN4PrME and DEN4PrMEsol coding sequence were inserted into the 
intermediate plasmid pJET and sequenced ( Figure 21).  Sequencing analysis showed a 
mutation in the sequence of DenV 4 E protein domain III (see figure20, a). A single 
nucleotide mutation resulted in substitution from arginine to threonine (R300T, number 
correspond to E amino acid sequence). This mutation was corrected by PCR mutagenesis 
(see figure 17 and 20,b). The corrected DEN4 PrME and DEN4 PrMEsol were inserted 
A.	 B.	
Figure 20, Dengue 4 E protein DIII mutation. A. The evidence of the R300T 
mutation. The sequence histogram of Den4 E protein showed a substitution of 
cytosine by guanine, which result in changing the threonine a.a to arginine, which 
has different polarity. B. Separation of the mutagenesis PCR reaction in 0.8% 
agarose gel, lane 1 and lane 2 represent the product1 and product2 of the 
extension PCR. Lane 3 represent the product of the overlapping PCR with is about 
2Kbp.  
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into pJET and sequenced. Analyzing of these plasmids showed that the mutation was 
corrected, the rest of inserts sequence was correct. Then, DEN2PrME, DEN2PrMEsol, 
DEN4PrME and DEN4PrMEsol coding sequences were inserted into pB(+)MVvac2 
downstream the N gene.  Four construct were produced and were analyzed by restriction 
endonuclease digestion (see figure 22 and 23).  The recombinant MVs plasmids were 
double digested with MluI and AatII enzymes, electrophoresis analysis showed two 
bands with approximate molecular size of 20 (for the backbone plasmid) and 2.1 and 2 
kbp representing  PrME or PrMEsol inserts, respectively. Selected clones sequence were 
analyzed and showed no mutations in the inserts sequences.  
 
 
Figure 21, Represent the map of Dengue virus insert. The full length insert  includes 12 a.a 
of Capsid protein C terminal which represent the signal sequence to direct the proteins into the 
ER. full length Premature membrane (PreM). Full length envelope (E) Protein including the 
steam and transmembrane domain. The soluble insert sequence are similar to the full length 
except for the E protein sequence. The E protein of the soluble insert is lacking 40 a.a at the C 
terminal of the E protein which represent the transmembrane (TM) domain. For clarity, the 
amino acid sequence represent the Dengue 2 virus amino acid sequences. 
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3.2 Rescue of four Vectored MVs expressing Dengue 2 and Dengue 4 glycoprotein. 
The four plasmid constructs were used to generate recombinant measles virus derived 
from a vaccine strains. Measles virus rescue system details are in the material and 
methods chapter. MVvac2DEN2(PrME)N and MVvac2DEN4PrME)N viruses were 
rescued  and amplified to obtain viral stocks with a titer of  107TCID50/ml, after one 
passage in the tissue culture. The MVvac2DEN2(PrMEsol)N virus was rescued  
Figure 22, Restriction endonuclease screening of recombinant MVs plasmid vectoring 
Dengue 2 coding sequence. A, agarose gel separation of digested recombinant measles 
vectoring DEN2PrME insert downstream N gene by Hind III, lane 1 through 6 are 
experimental lanes. Lane 7 is a negative control. B, selected clones from lane 2 and 6 in A 
were analyzed by Mlu I and AatII double digestion. Lane 1 and 2 were experimental 
lanesl. Lane 3 was negative control. C, agarose gel separation of digested recombinant 
measles plasmid vectoring DEN2(PrMEsol) insert downstream N gene by Mlu I and Aat 
II enzymes. Lane 1 and 2 were negative control, lane 3 through 6 were experimental lanes. 
Lane 2 and 3 showed positive result.    
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with a titer of 106 TCID50/ml after three passages in the tissue culture. The 
MVvac2DEN4(PrMEsol)N virus was rescued with a titer of around 104 TCID50/ml after 
three passages in tissue culture, the virus aliquots were stored at -80 C and were not go 
through further experiments on this study.  
 
Figure 23. Restriction endonuclease screening of recombinant MVs plasmid vectoring 
Dengue 4 coding sequence. A, agarose gel separation of digested recombinant measles 
vectoring DEN4PrME insert downstream N gene by Mlu I and AatII enzymes. Lane 1 
through 8 are experimental lanes. Lane 9 and 10 was negative control. Lane 1, 3, 4, 5, 6 
and 7 show a positive result. B, agarose gel separation of digested recombinant measles 
plasmid vectoring DEN4 (PrMEsol) insert downstream N gene by Mlu I and Aat II 
enzymes. Lane 1 through 4 are experimental lanes. Lane 5 and 6 are negative control. 
Lane 1, 2, 3 and 4 showed positive result. 
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 To assess the replication efficiency of these vectored MVs ,a multi-step growth 
kinetic analysis was performed (cells were infected by MOI 0.03). As shown in figure 24, 
the maximum titers reached by MVvac2DEN2(PrME)N and MVvac2Den4(PrME)N 
were very close to those of the parental strain, MVvac2 (8 X 106 TCID50/mL and 10
7 
TCID50/mL, respectively 48 hr after infection). Thus, the replication efficiency of these 2 
viruses was equivalent to the parental strain. In contrast to, the 
MVvac2DEN2(PrMEsol)N has a lower replication efficiency than the parental strain. 
Peak titer of about 105 TCID50/ml were reached 48 hours postinfection for extracellular 
and of about 8 X 103 TCID50/ml were reached 48 hour postinfection for intracellular 
MVvac2DEN2(PrMEsol)N. 
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Figure 24, Growth kinetic of cell-associated (Intracellular) and cell-free (extracellular) 
virus production in Vero/hSLAm cells. A, time course of intracellular virus production in 
Vero/hSLAm cells infected with parental strain virus (MVvac2), recombinant MVs: 
MVvac2DEN2(PrME)N (D2-2), MVvac2DEN2(PrMEsol)N (A.4) and MVvac2DEN4(PrME)N 
(1.6.2). B, time course of extracellular virus production in Vero/hSLAm cells infected with 
parental strain virus (MVvac2), recombinant MVs: MVvac2DEN2(PrME)N (D2-2), 
MVvac2DEN2(PrMEsol)N (A.4) and MVvac2DEN4(PrME)N (1.6.2). The viral titers, indicated 
on the vertical axis were measured 12, 24, 36, 48, 72 or 96 hrs. postinfection for both graph A 
and B. For clarity, Averages and standard deviations of three independent experiments are 
indicated in this figure.  
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Figure 25, Detection of Dengue 2 PrME and PrMEsol mRNA expression in MVs, 
Dengue2 virus and two recombinant MVs infected cells. The upper panel represent the 
separation of RT-PCR products on 1.2 % agarose gel. Lane1 is the PCR negative control, 
lane2 is MVs PCR product, lane3 is Dengue 2 PCR product, lane4 is D2-2 PCR product and 
lane4 is the A.4 PCR product. Dengue 2 and D2-2 product are at the same molecular size, 
while A.4 product is lower that the Dengue 2 and D2-2 products size. The lower panel 
represent the separation of total RNA extracted from cells infected with MVs, Dengue2, D2-2 
and A.4 viruses. RNA extracted from cells infected with MVvac2 present in lane 1, Dengue2 
virus present in lane2, D2-2 virus present in lane 3 and A.4 virus present in lane4. Lane 2 
show no RNA, because Dengue 2 virus was collected from the supernatant of the infected 
cells. The subunit of the cellular ribosomal RNA can be detected at lane1, 3 and 4.   
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3.3 Determination of Dengue 2 and 4 glycoprotein expression by vectored MVs. The 
expression of Dengue2 and Dengue 4 PrME glycoprotein was detected at the level of 
mRNA using RT-PCR and/or at the level of proteins using Western blot and indirect 
immunofluorescenc-e assay. For RT -PCR analysis, total RNA was obtained from 
infected cells at 48 h post infection. The same primers that were used to amplify this 
sequence from full-length plasmids were used in a single-step RT-PCR reaction. As 
shown in figure 25, The separation of the RT-PCR products in 1.2% agarose gel showed 
that RNA extraction from Dengue 2 infected supernatant,  MVvac2DEN2 (PrME)N and 
MVvac2DEN2(PrMEsol)N infected cells have amplicons corresponding to the PrME 
mRNA. As expected, the amplified band of the MVvac2DEN2 (PrMEsol) N has a lower 
molecular size than the one obtained from Dengue2 and MVvac2DEN2 (PrME) N. The 
difference in molecular size results from the deletion of the E protein transmembrane and 
cytoplasmic domains in case of the PrMEsol insert. Total RNA obtained from infected 
Figure 26, Western blot of protein extract by lysis of Vero h-Slam cells non-
infected, infected with MVvac2 , D2-2 , A.4 or Dengue 2 virus. The upper panel 
represenst the detection of Measles H protein using anti-H antibodies. The lower 
panel represents the detection of Actin protein using anti-actin antibodies. As 
shown lane 1 is non-infected cells protein extract, lane 2 is MVvac2 infected 
cells protein extract, lane 3 is D2-2 infected cells protein extract, lane 4 is A.4 
infected cells protein extract, lane 5 is Dengue 2 virus infected cells protein 
extract. 
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cells showed an expected electrophoresis migration pattern, with the ribosomal RNA 
bands evident (figure 25, lower panel). The Dengue 2 and 4 PrME glycoproteins 
expressed from vectored MVs was then characterized by western blotting. Protein 
extracts of infected cells were blotted into nitrocellulose membrane and incubated with 
anti DEN1,2,3,4 E mouse monoclonal antibody to detect the expression of Dengue 
glycoproteins. As shown in figure27, anti-E antibodies recognize the E glycoprotein with 
molecular mass of 59 KDa (53KDa the mass of the protein and 6 KDa the mass for two 
glycosylation sites). As expected the expression of E protein was detected in the extract 
of Dengue2, MVvac2DEN2 (PrME) N and MVvac2DEN2   (PrMEsol) viruses infected 
cells but not in the extract of MVvac2 infected cells. However, we were unable to 
determine the expression of DEN4 E protein on this assay. MVs H and N glycoproteins 
were detected using anti H mouse or anti N rabbit polyclonal antibody to detect the 
expression of measles proteins. As shown in figure 26 and 27, Anti N recognize the N 
glycoprotein with molecular mass of 62 KDa and the anti H recognize the H glycoprotein 
with molecular mass of 80 kDa in cells extract infected with MVvac2, 
MVvac2DEN2(PrME)N and MVvac2DEN2(PrMEsol)N viruses but not in the Dengue 2 
virus infected cells extraction. Actin detection was done using anti-actin mouse 
monoclonal antibody as a control of the protein concentration in different cell extract (see 
figure 26 and27). Indirect immunofluorescence assay was used to detect the expression of 
Dengue 2 and Dengue 4 PrM and E glycoproteins in Vero/hSLAM cells infected with 
MVvac2, Dengue2, Dengue 4, MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol)N and 
MVvac2DEN4(PrME)N viruses. As shown in figures 29 and 30, the expression of 
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Dengue2 and 4 E proteins were determined in cells infected with recombinant MVs: 
MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol)N and MVvac2DEN4(PrMEsol)N and 
in cells infected with Dengue 2 and 4 viruses. The expression of Dengue2 and 4 PrM 
glycoprotein was confirmed in cells infected by Dengue 2 and 4 as well as recombinant 
MVs: MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol)N and 
MVvac2DEN4(PrMEsol)N as shown in figure 28and 31. 
 
 
 
 
 
 
Figure 27, Western blot of protein extract by lysis of Vero h-Slam cells                         
non-infected, infected with MVvac2 , D2-2 , A.4 or Dengue 2 virus. The upper panel 
represent the detection of Dengue E protein using anti-E antibodies. The medial 
panel represent the detection of Measles N protein using anti-N antibodies. The 
lower panel represent the detection of Actin protein using anti-actin antibodies. 
As shown lane 1 is MVvac2 infected cells protein extract, lane 2 is Dengue 2 virus 
infected cell protein extract lane 3 is D2-2 infected cells protein extract, lane 4 is 
A.4 infected cells protein extract, lane 5 is 1.6.2 virus infected cells protein extract. 
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The syncytium obtained from cells infected by MVs and recombinant MVs, were 
screened for the expression of MV N glycoprotein. As shown in figures 28, 29, 30 and31, 
the expression of N glycoprotein was detected in all MV and recombinant MVs infected 
cells and not in Dengue2 and 4 infected cells. Non-infected cells showed negative results 
for anti-E, anti-PrM and anti-N screening. Recombinant MVs: MVvac2DEN2(PrME)N, 
MVvac2DEN2(PrMEsol)N and MVvac2DEN4(PrMEsol)N infected cells showed 
positive result for the dual expression of MVs N glycoprotein and Dengue virus E or PrM 
glycoprotein as shown in figures 28,29, 30 and 31. The cell’s nucleuses were stained blue 
by DAPI to visualize the cell nuclei.   
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Figure 28. Expression of Dengue2 PrM protein from recombinant MVs. Vero/hSLAM 
cells were non-infected (A) or infected with either Dengue2(B), MVvac2(C) D2-2(D) or A.4 
(E) viruses and processed for indirect immunofluorescence as described in Materials and 
Methods. MVs N was detected with rabbit anti-N antibody and Dengue 2 PrM was detected 
with mouse anti-PrM antibody, followed by anti-rabbit- and anti-mouse antibody– PE(red) 
/FITC(green) conjugate, respectively. The duel expression of N and PrM protein was detected 
by overlapping the GFP and RFP channels, as shown in marge Colum. The fixed cells were 
stained by DAPI blue, which gave the nuclei this blue color when using DAPI blue channel in 
the microscope. 
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Figure 29, Expression of Dengue2 E protein from recombinant MVs. Vero/hSLAM 
cells were non-infected (A) or infected with either Dengue2 (B), MVs(C), D2-2(D) or A.4 
(E) viruses and processed for indirect immunofluorescence as described in Materials and 
Methods. MVs N was detected with rabbit anti-N antibody and Dengue 2 E was detected 
with mouse anti-E antibody, followed by anti-rabbit- and anti-mouse antibody– PE(red) 
/FITC(green) conjugate, respectively. The duel expression of N and E protein was detected 
by overlapping the GFP and RFP channels, as shown in marge Colum. The fixed cells were 
stained by DAPI blue, which gave the nuclei this blue color when using DAPI blue channel 
in the microscope. 
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Figure 30, Expression of Dengue4 E protein from recombinant MVs. Vero/hSLAM cells 
were non-infected (A)or infected with either Dengue 4(B), MVvac2(C), or 1.6.2(D) viruses and 
processed for indirect immunofluorescence as described in Materials and Methods. MVs N was 
detected with rabbit anti-N antibody and Dengue4 E was detected with mouse anti-E antibody, 
followed by anti-rabbit- and anti-mouse antibody– PE (red) /FITC(green) conjugate, 
respectively. The duel expression of N and E protein was detected by overlapping the GFP and 
RFP channels, as shown in marge Colum. The fixed cells were stained by DAPI blue which gave 
the nuclei this blue color when using DAPI blue channel in the microscope. 
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Figure 31, Expression of Dengue 4 PrM protein from recombinant MVs. Vero/hSLAM 
cells were non-infected (A)or infected with either Dengue 4 (B), MVvac2 (C), or 1.6.2(D) 
viruses and processed for indirect immunofluorescence as described in Materials and 
Methods. MVs N was detected with rabbit anti-N antibody and Dengue4 PrM was detected 
with mouse anti-PrM antibody, followed by anti-rabbit- and anti-mouse antibody– PE(red) 
/FITC(green) conjugate, respectively. The duel expression of N and PrM protein was 
detected by overlapping the GFP and RFP channels, as shown in marge Colum. The fixed 
cells were stained by DAPI blue, which gave the nuclei this blue color when using DAPI 
blue channel in the microscope. 
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Chapter 4. DISCUSSION 
Dengue infections are significantly affecting South -East Asia (SEA), the Western 
Pacific, and in some countries in South Africa.  “Of the total world population of 6.2 
billion, countries of the South-East Asia Region (SEAR) account for 1.5 billion (24%). 
On that scale, of the 2.5 billion people (living in the tropics and sub-tropics) at risk of 
DF/DHF, 52%, i.e. 1.3 billion populations, live in SEAR” (136). These countries include 
Thailand, India and Indonesia. Dengue also causes major health problems in the Western 
pacific countries, including Malaysia, Philippines and Vietnam. In South America, 
countries, such as Mexico and Peru, dengue infections are the cause of hospitalization 
and death among children. Preventing Dengue infection is a public health priority. 
Because there is no specific treatment for the disease and the control methods such as 
chemical sprays and windows screams fail to efficiently limit the transmission of the 
virus, there is a priority to develop an efficient vaccine. Major challenges for this 
development are related to market- and technology- mainly. The market issues include 
vaccine pricing and demand projections. Since, the most affected countries are 
developing countries, there is a need to generate a cost-efficient vaccine. In addition, the 
geographical expanding of dengue virus infection increases the concerns about vaccine 
demand projection. Technology related issues include the safety and the need to produce 
simultaneous protective immune responses to all four serotypes. Candidate vaccines that 
use diverse approaches are currently in various stages of development (table one) are 
facing difficulties immunizing epidemic areas. Live attenuated vaccines including 
attenuated viruses, recombinant viruses and chimeric live attenuated virus vaccine 
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approach face viral interference and recombination. For instance, the chimeriVax 
tetravalent Dengue vaccine candidate generated by Acambis and Sanofi Pasture is facing 
the challenge of viral replication interference. When monovalent candidates are tested, 
positive result are encouraging, however, a tetravalent formulation tested in human, 
higher doses are required to induce a high level of neutralizing antibodies against the four 
Dengue serotypes (124). The viral replication interference happen because the four live 
attenuated viruses are competing to enter the host cell through the same cell receptor 
which result in decreasing the replication profile of the live attenuated vaccine 
candidates. Recombination is another concern when using a tetravalent live attenuated 
virus vaccine. The RNA viruses can naturally recombine within and between species. 
One example is the recombination between a Sindbis-like virus and the eastern equine 
encephalitis virus that resulted in emergence of Western equine encephalitis virus (137). 
The homologous recombination among flavivirus has been reported by Seligman. S. J., et 
la in 2004, which introduce concerns about the tetravalent live attenuated dengue vaccine 
safety(138). In contrast, inactivated vaccines face the problem of cost efficiency since a 
high dose of purified and inactivated virus introduce along with adjuvant makes the cost 
of producing this alternative very high. Subunit vaccines share the same challenge. The 
purification process and the need for adjuvants to induce high neutralizing antibody titer, 
increase the cost of the subunit vaccine development. Both inactivated and recombinant 
subunit dengue vaccine candidates are not acceptable vaccine for endemic area.  
 
 
94 
 
 
Plasmidic DNA expressing Den 2 glycoprotein face cost and safety challenges as well as 
poor antigenic presentation. Kochel et al. at NIMRC try to enhance the trafficking and the 
presentation of the den 2 antigen by fusing the protein to a lysosome associated 
membrane protein which enhance the immunogenicity of the vaccine, but it is still 
considered of low immunogenicity (126). 
In this research, the virus vector MVvac2 generated from Schwarz vaccine strain 
is used as a backbone to generated a Dengue vaccine. We propose that MV- DenV 
divalent vaccine will overcome all the challenges faced that was mentioned for the DenV 
vaccine candidates. The recombinant MVs was experimentally tested for genetic stability, 
safety and efficacy. It showed genetic stability which is unexpected for RNA viruses, and 
ability to carry a high load of genetic material. In addition to the low production cost per 
vaccination dose (review the introduction section for more details). All this factors will 
make MV- DENV divalent vaccine a suitable vaccine candidates to be used in endemic 
countries. However, we are aware that the preimmunity to measles virus could be a 
concern if the vaccine will be used in adolescent and adults. In animal models, the 
preimmunity from vaccination with MV vaccine does not prevent a boost with 
recombinant MV. In fact, boosts enhance the immune response against MV and the 
transgene(139, 140). For instance, measles immunity can be boosted in children who are 
preimmune after a first vaccination during infancy. In the present study, two different 
forms of either DEN2 or DEN4 were introduced downstream MV N gene that resulted in 
four different recombinant MVs vector. These virus vectors were used to generate 
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recombinant MVs. The aim of generating membrane bound and secreted DenV E 
glycoprotein is to test which form would induce a higher immune response in animal 
models. The recombinant MVs expressing membrane bound (full length) E protein will 
replicate in the cytoplasm of the host cells with the potential of displaying DenV E 
glycoprotein on the surface of the infected cells. As a consequence, the infected cells will 
be a target for CD8+ T-cells and will generate a cellular immune response against Den V 
infection. The recombinant MVs expressing secreted (soluble) E protein will replicate in 
the cytoplasm of the infected cells and will result in secretion of DenV E glycoprotein to 
the extracellular space. As a consequence, neutralizing antibodies directed to Den V E 
protein will be secreted from B-cells and will generate a humoral immune response 
against Den V infection. The results of this study showed that (i) recombinant MVs 
carrying Den V glycoproteins coding sequence downstream N gene can be rescued and 
propagated in tissue culture, (ii) the replication profile of the recombinant MVs was 
similar to that of the parental strain in case of recombinant MVs expressing full length E 
protein but not soluble E, (iii) the two forms of E protein were successful expressed by 
the recombinant MVs. The four amplified coding sequence of Den2V PrME, Den2V 
PrMEsol, Den4V PrME and Den4V PrMEsol were analyzed to identify any mutation in 
the sequence. Both Den4V PrME and Den4V PrMEsol sequence had a nucleotide 
substitution mutation at the E protein domain III which would affect the immune 
response against DenV infection. The R300T mutation (figure20) resulted in substitution 
of threonine that is polar uncharged amino acid by arginine, which is a positive charged 
amino acid. We corrected this mutation. The replication profile of the recombinant MVs 
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varied depending on the expressed Den Ag. As showed in the figure 26, the replication 
profile of recombinant MVs expressing Den2V PrMEsol Ag was lower than the 
replication profile of the parental strain and the recombinant MVs expressing either Den2 
or Den4 full-length antigens. This observation in the replication profile of MVvac2DEN2 
(PrMEsol)N can have two explanations. First, we think that the secreted E glycoproteins 
were accumulated in the SlAM receptor in the surface of the nearby cells, which may 
interfere with the entry of newly synthesized recombinant MV. Which is using SLAM 
receptor to enter the nearby cells. Second, we think that the secreted E glycoprotein can 
bind to the MV glycoprotein in the secretory exosome. Which interface with the ability of 
the recombinant MV to enter the nearby cells. However, we have now demonstrated that 
MVvac2DEN2(PrME)N, MVvac2DEN2(PrMEsol)N and MVvac2DEN4(PrME)N are 
expressing DenV PrM and E glycoprotein. As shown in figures 28, 29, 30, and 31. The 
expression of both Den2 and Den4 PrME glycoprotein were detected by using 
monoclonal Ab against either E or PrM glycoprotein in the indirect immunofluorescence 
assay. The difference in the molecular mass between the PrME and the PrME soluble was 
demonstrated by RT-PCR as shown in figure#. Western blot assay was performed to 
detect MV N and H glycoprotein as well as Den2 E glycoprotein. However, the detection 
of E glycoprotein in western blot assay was weak. To address these issue we used indirect 
immunofluorescence assay to demonstrate the expression of Den2 and Den4 glycoprotein 
by recombinant MVs. In conclusion, we have proof that recombinant MVs expressing 
DenV  glycoprotein have a good replication and expression profile and these recombinant 
MVs can be used in future experiments. Future prospective experiments will include: 
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endoglycosidase digestion experiments with the goal of corroborating the quality of the 
antigens vectored by measles; the biophysical analysis of secreted material to 
demonstrate the presence of empty viral-like particles containing dengue antigens, and 
localization of the expressed full length and soluble E glycoprotein using protein tagging 
methods. These experiments can be done for only recombinant MV expressing Den2V 
antigen as a proof of concept Immunogenicity study can be done by immunization of 
mice susceptible to MV with the recombinant MVs expressing either Den2V or Den4V 
antigens. Nevertheless, the experimental results described in this thesis give substrate for 
animla experimentation.  The first step is the demonstration that our vectors can elicit 
neutralizing immune responses against the corresponding dengue virus while still being 
able to elicit immune responses against the vector backbone that can be considered 
protective. The more suitable animal model for this experiment is our measles-susceptible 
genetically modified mouse model. This host expresses one of MV cell receptors (CD46) 
with a human-like distribution in a type I interferon defective background 9which allows 
for MV replication). This small host (GeCD46-INFrako mice) is a gold standard to discern 
vaccine candidates with good in vivo replication and hence advantageous vaccine 
potential. During a second phase of animal experimentation, protective responses against 
the relevant dengue virus will be assessed in AG129 transgenic mice passively 
immunized with reactive sera obtained from GeCD46-INFrako mice. AG129 mice are 
defective in type I and type II interferon responses and can replicate mouse-adapted 
dengue viruses, but most importantly, this small model reproduces vascular changes upon 
dengue infection, hence vaccine responses can be rated in this model.  
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MVs vector could be modified to generate more robust immune responses, if 
needed. These could br achieved by enhancing the fusion ability of MV, which may 
increase the spread, and the replication of the virus in Human.  Shumpei Watanbe et la, 
demonstrated that certain mutation in the Fusion proteins enhanced the fusion activity 
and promotes the spread of MV in human. In this study Shumpei demonstrated that 
recombinant MVs with mutation in the ectodomain of F protein have enhanced fusion 
ability. These viruses can induce cell fusion in SLAM and nectin 4-negative cells unlike 
parental strain (141). In addition Shumpei demonstrated that mutation in M protein can 
induce the fusion activity of wild type MV F protein. These result suggest that, the 
enhancement of MV fusion would increase the virus replication profile. Because the virus 
will be able to replicate on cells that express or do not SLAM and nectin-4 receptor in it 
surface. The recombinant MV expressing DenV antigen can be modified in the same way 
to enhance the virus fusion activity which will result in improving the replication ability 
of the viruses. The fusion activity of the F protein can be enhanced by deletion the 
cytoplasmic tail of the F protein which interacts with the M protein. Instead of deleting M 
protein which may affect the virus particles formation, the deletion of the cytoplasmic tail 
of the F protein would prevent the interaction of the F protein and enhance the fusion 
ability of The MV. We hypothesize these modified viruses would generate more robust 
immune response against both MVs and DenV. 
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